<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F260EB84-7F70-42D1-A9D0-00BA8040839C"><gtr:id>F260EB84-7F70-42D1-A9D0-00BA8040839C</gtr:id><gtr:name>Southmead Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4AAE76DE-5807-40EF-B3FE-824A330ECEF3"><gtr:id>4AAE76DE-5807-40EF-B3FE-824A330ECEF3</gtr:id><gtr:name>South Tees Hospitals NHS Foundtn Trust</gtr:name><gtr:address><gtr:line1>James Cook Hospital</gtr:line1><gtr:line2>Marton Road</gtr:line2><gtr:postCode>TS4 3BW</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E7C3165-D40E-4C74-93D1-FF28CDF429BA"><gtr:id>2E7C3165-D40E-4C74-93D1-FF28CDF429BA</gtr:id><gtr:name>Queen Elizabeth Hospital (Malaysia)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BDB62FBC-921E-49FF-AD56-909ED429E427"><gtr:id>BDB62FBC-921E-49FF-AD56-909ED429E427</gtr:id><gtr:name>Institute of Tropical Medicine</gtr:name><gtr:address><gtr:line1>Nationalestraat 155</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A601437-2EFC-42F2-9E23-3B4D475CF80D"><gtr:id>7A601437-2EFC-42F2-9E23-3B4D475CF80D</gtr:id><gtr:name>Gloucestershire Royal Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BEEE3C87-89FE-49E8-8479-3CB6523E8610"><gtr:id>BEEE3C87-89FE-49E8-8479-3CB6523E8610</gtr:id><gtr:name>African Eye Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB"><gtr:id>FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB</gtr:id><gtr:name>University College Dublin</gtr:name><gtr:address><gtr:line1>Belfield</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/40A7BFF7-E338-48CC-87CE-2EC5F45A6B56"><gtr:id>40A7BFF7-E338-48CC-87CE-2EC5F45A6B56</gtr:id><gtr:name>St Mary's Hospital, London</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D4584B27-3F2A-4408-B3E3-19B6800F5217"><gtr:id>D4584B27-3F2A-4408-B3E3-19B6800F5217</gtr:id><gtr:name>Amsterdam Institute for Global Health and Development (AIGHD)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6C84061-938E-4BFA-8430-55A2C2B512D7"><gtr:id>B6C84061-938E-4BFA-8430-55A2C2B512D7</gtr:id><gtr:name>Chelsea and Westminster Health Charity</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/43ECF77B-CD97-49C9-812D-40CB69D1D03B"><gtr:id>43ECF77B-CD97-49C9-812D-40CB69D1D03B</gtr:id><gtr:name>San Raffaele Hospital</gtr:name><gtr:address><gtr:line1>29 Via Prinetti</gtr:line1><gtr:region>outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F5569A12-0A1B-4474-B608-84BB0C44B3A7"><gtr:id>F5569A12-0A1B-4474-B608-84BB0C44B3A7</gtr:id><gtr:name>University of Minnesota</gtr:name><gtr:address><gtr:line1>127 Vincent Hall</gtr:line1><gtr:line2>206 Church St. S.E</gtr:line2><gtr:line4>Minneapolis</gtr:line4><gtr:line5>MN 55455</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/52D47D67-C160-4C09-A5A6-03E1C35E47D5"><gtr:id>52D47D67-C160-4C09-A5A6-03E1C35E47D5</gtr:id><gtr:name>Royal Hallamshire Hospital</gtr:name><gtr:address><gtr:line1>Glossop Road</gtr:line1><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2JF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F0C585DF-A9BB-4FAC-A3D7-30AA738D1173"><gtr:id>F0C585DF-A9BB-4FAC-A3D7-30AA738D1173</gtr:id><gtr:name>Ibn Rochd University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/681C1535-3857-4B97-ADE1-82DBD84698A4"><gtr:id>681C1535-3857-4B97-ADE1-82DBD84698A4</gtr:id><gtr:name>Italian National Health Service</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/504BDD16-1C05-425A-B092-21D8F861A89B"><gtr:id>504BDD16-1C05-425A-B092-21D8F861A89B</gtr:id><gtr:name>St Thomas' Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/452B99A5-84DA-42F4-857A-46B2B09E481B"><gtr:id>452B99A5-84DA-42F4-857A-46B2B09E481B</gtr:id><gtr:name>UK Community Advisory Board UKCAB</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A468659-CE74-4F8F-91FB-F14404250B19"><gtr:id>7A468659-CE74-4F8F-91FB-F14404250B19</gtr:id><gtr:name>University of Athens</gtr:name><gtr:address><gtr:line1>Panepistimiopolis</gtr:line1><gtr:line4>Athens</gtr:line4><gtr:line5>157 71</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Greece</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F463A0E1-E89E-406B-B803-760625885B6C"><gtr:id>F463A0E1-E89E-406B-B803-760625885B6C</gtr:id><gtr:name>Hospital Universitario La Paz</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DFB77BA5-5A7A-44C6-8FD5-8300855D6333"><gtr:id>DFB77BA5-5A7A-44C6-8FD5-8300855D6333</gtr:id><gtr:name>Washington Dc Va Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7"><gtr:id>D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7</gtr:id><gtr:name>Birmingham Heartlands Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5"><gtr:id>8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5</gtr:id><gtr:name>North Manchester General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8BF1E3A-E97F-40DF-8329-719D54E2DA60"><gtr:id>A8BF1E3A-E97F-40DF-8329-719D54E2DA60</gtr:id><gtr:name>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A393419-8F67-4FB5-9D17-B9A04A7B3CA9"><gtr:id>5A393419-8F67-4FB5-9D17-B9A04A7B3CA9</gtr:id><gtr:name>University of New South Wales</gtr:name><gtr:address><gtr:line1>Gate 9 High St</gtr:line1><gtr:line2>Kensington</gtr:line2><gtr:line4>Sydney</gtr:line4><gtr:line5>NSW 2052</gtr:line5><gtr:postCode>2052</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EB6D1A98-E18B-4D07-BB8E-3F2F49755097"><gtr:id>EB6D1A98-E18B-4D07-BB8E-3F2F49755097</gtr:id><gtr:name>CINECA</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E210CF35-6FAB-4850-90AE-9F74E7AA02AC"><gtr:id>E210CF35-6FAB-4850-90AE-9F74E7AA02AC</gtr:id><gtr:name>Royal Berkshire Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF50F5F2-9CE2-48EC-8A5A-409480A56BA8"><gtr:id>FF50F5F2-9CE2-48EC-8A5A-409480A56BA8</gtr:id><gtr:name>Royal Victoria Teaching Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9A907B69-0887-458B-A485-73702C1849A9"><gtr:id>9A907B69-0887-458B-A485-73702C1849A9</gtr:id><gtr:name>University Hospital of Bern</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/591A3A9A-B9DC-4D31-8660-2E747AAEDFAE"><gtr:id>591A3A9A-B9DC-4D31-8660-2E747AAEDFAE</gtr:id><gtr:name>Royal Sussex County Hospital</gtr:name><gtr:address><gtr:line1>Royal Sussex County Hospital</gtr:line1><gtr:line2>Eastern Road</gtr:line2><gtr:postCode>BN2  5BE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F260EB84-7F70-42D1-A9D0-00BA8040839C"><gtr:id>F260EB84-7F70-42D1-A9D0-00BA8040839C</gtr:id><gtr:name>Southmead Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4AAE76DE-5807-40EF-B3FE-824A330ECEF3"><gtr:id>4AAE76DE-5807-40EF-B3FE-824A330ECEF3</gtr:id><gtr:name>South Tees Hospitals NHS Foundtn Trust</gtr:name><gtr:address><gtr:line1>James Cook Hospital</gtr:line1><gtr:line2>Marton Road</gtr:line2><gtr:postCode>TS4 3BW</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E7C3165-D40E-4C74-93D1-FF28CDF429BA"><gtr:id>2E7C3165-D40E-4C74-93D1-FF28CDF429BA</gtr:id><gtr:name>Queen Elizabeth Hospital (Malaysia)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BDB62FBC-921E-49FF-AD56-909ED429E427"><gtr:id>BDB62FBC-921E-49FF-AD56-909ED429E427</gtr:id><gtr:name>Institute of Tropical Medicine</gtr:name><gtr:address><gtr:line1>Nationalestraat 155</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A601437-2EFC-42F2-9E23-3B4D475CF80D"><gtr:id>7A601437-2EFC-42F2-9E23-3B4D475CF80D</gtr:id><gtr:name>Gloucestershire Royal Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BEEE3C87-89FE-49E8-8479-3CB6523E8610"><gtr:id>BEEE3C87-89FE-49E8-8479-3CB6523E8610</gtr:id><gtr:name>African Eye Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB"><gtr:id>FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB</gtr:id><gtr:name>University College Dublin</gtr:name><gtr:address><gtr:line1>Belfield</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/40A7BFF7-E338-48CC-87CE-2EC5F45A6B56"><gtr:id>40A7BFF7-E338-48CC-87CE-2EC5F45A6B56</gtr:id><gtr:name>St Mary's Hospital, London</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D4584B27-3F2A-4408-B3E3-19B6800F5217"><gtr:id>D4584B27-3F2A-4408-B3E3-19B6800F5217</gtr:id><gtr:name>Amsterdam Institute for Global Health and Development (AIGHD)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6C84061-938E-4BFA-8430-55A2C2B512D7"><gtr:id>B6C84061-938E-4BFA-8430-55A2C2B512D7</gtr:id><gtr:name>Chelsea and Westminster Health Charity</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/43ECF77B-CD97-49C9-812D-40CB69D1D03B"><gtr:id>43ECF77B-CD97-49C9-812D-40CB69D1D03B</gtr:id><gtr:name>San Raffaele Hospital</gtr:name><gtr:address><gtr:line1>29 Via Prinetti</gtr:line1><gtr:region>outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F5569A12-0A1B-4474-B608-84BB0C44B3A7"><gtr:id>F5569A12-0A1B-4474-B608-84BB0C44B3A7</gtr:id><gtr:name>University of Minnesota</gtr:name><gtr:address><gtr:line1>127 Vincent Hall</gtr:line1><gtr:line2>206 Church St. S.E</gtr:line2><gtr:line4>Minneapolis</gtr:line4><gtr:line5>MN 55455</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52D47D67-C160-4C09-A5A6-03E1C35E47D5"><gtr:id>52D47D67-C160-4C09-A5A6-03E1C35E47D5</gtr:id><gtr:name>Royal Hallamshire Hospital</gtr:name><gtr:address><gtr:line1>Glossop Road</gtr:line1><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2JF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ACCAA472-353D-4CD6-814A-04677AE5E921"><gtr:id>ACCAA472-353D-4CD6-814A-04677AE5E921</gtr:id><gtr:name>MRC/UVRI Uganda Research Unit on AIDS</gtr:name><gtr:address><gtr:line1>Uganda Virus Research Institute</gtr:line1><gtr:line2>51-59 Nakiwogo Road, PO box 49</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F0C585DF-A9BB-4FAC-A3D7-30AA738D1173"><gtr:id>F0C585DF-A9BB-4FAC-A3D7-30AA738D1173</gtr:id><gtr:name>Ibn Rochd University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/681C1535-3857-4B97-ADE1-82DBD84698A4"><gtr:id>681C1535-3857-4B97-ADE1-82DBD84698A4</gtr:id><gtr:name>Italian National Health Service</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/504BDD16-1C05-425A-B092-21D8F861A89B"><gtr:id>504BDD16-1C05-425A-B092-21D8F861A89B</gtr:id><gtr:name>St Thomas' Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/452B99A5-84DA-42F4-857A-46B2B09E481B"><gtr:id>452B99A5-84DA-42F4-857A-46B2B09E481B</gtr:id><gtr:name>UK Community Advisory Board UKCAB</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A468659-CE74-4F8F-91FB-F14404250B19"><gtr:id>7A468659-CE74-4F8F-91FB-F14404250B19</gtr:id><gtr:name>University of Athens</gtr:name><gtr:address><gtr:line1>Panepistimiopolis</gtr:line1><gtr:line4>Athens</gtr:line4><gtr:line5>157 71</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Greece</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F463A0E1-E89E-406B-B803-760625885B6C"><gtr:id>F463A0E1-E89E-406B-B803-760625885B6C</gtr:id><gtr:name>Hospital Universitario La Paz</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DFB77BA5-5A7A-44C6-8FD5-8300855D6333"><gtr:id>DFB77BA5-5A7A-44C6-8FD5-8300855D6333</gtr:id><gtr:name>Washington Dc Va Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7"><gtr:id>D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7</gtr:id><gtr:name>Birmingham Heartlands Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5"><gtr:id>8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5</gtr:id><gtr:name>North Manchester General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8BF1E3A-E97F-40DF-8329-719D54E2DA60"><gtr:id>A8BF1E3A-E97F-40DF-8329-719D54E2DA60</gtr:id><gtr:name>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C705F4C9-3E9D-4C2A-90B0-49C636E962EE"><gtr:id>C705F4C9-3E9D-4C2A-90B0-49C636E962EE</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>9 Prescot Street
Aldgate</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>E1 8PR</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A393419-8F67-4FB5-9D17-B9A04A7B3CA9"><gtr:id>5A393419-8F67-4FB5-9D17-B9A04A7B3CA9</gtr:id><gtr:name>University of New South Wales</gtr:name><gtr:address><gtr:line1>Gate 9 High St</gtr:line1><gtr:line2>Kensington</gtr:line2><gtr:line4>Sydney</gtr:line4><gtr:line5>NSW 2052</gtr:line5><gtr:postCode>2052</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EB6D1A98-E18B-4D07-BB8E-3F2F49755097"><gtr:id>EB6D1A98-E18B-4D07-BB8E-3F2F49755097</gtr:id><gtr:name>CINECA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E210CF35-6FAB-4850-90AE-9F74E7AA02AC"><gtr:id>E210CF35-6FAB-4850-90AE-9F74E7AA02AC</gtr:id><gtr:name>Royal Berkshire Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF50F5F2-9CE2-48EC-8A5A-409480A56BA8"><gtr:id>FF50F5F2-9CE2-48EC-8A5A-409480A56BA8</gtr:id><gtr:name>Royal Victoria Teaching Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9A907B69-0887-458B-A485-73702C1849A9"><gtr:id>9A907B69-0887-458B-A485-73702C1849A9</gtr:id><gtr:name>University Hospital of Bern</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/591A3A9A-B9DC-4D31-8660-2E747AAEDFAE"><gtr:id>591A3A9A-B9DC-4D31-8660-2E747AAEDFAE</gtr:id><gtr:name>Royal Sussex County Hospital</gtr:name><gtr:address><gtr:line1>Royal Sussex County Hospital</gtr:line1><gtr:line2>Eastern Road</gtr:line2><gtr:postCode>BN2  5BE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4CFEE661-9281-4E12-B253-109123EF97A4"><gtr:id>4CFEE661-9281-4E12-B253-109123EF97A4</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:otherNames>Sarah</gtr:otherNames><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/24284D44-C9EF-44B4-810B-F4199F33D115"><gtr:id>24284D44-C9EF-44B4-810B-F4199F33D115</gtr:id><gtr:firstName>Nick</gtr:firstName><gtr:surname>Paton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/58B69503-B9E3-43E3-AEB2-82D521E4C95E"><gtr:id>58B69503-B9E3-43E3-AEB2-82D521E4C95E</gtr:id><gtr:firstName>Diana</gtr:firstName><gtr:surname>Gibb</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FF7C9766-B80F-4EBF-A578-E69BA282D59A"><gtr:id>FF7C9766-B80F-4EBF-A578-E69BA282D59A</gtr:id><gtr:firstName>Janet</gtr:firstName><gtr:otherNames>Howard</gtr:otherNames><gtr:surname>Darbyshire</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/664FA0A0-B6F5-431F-AA4E-4D5070BAD879"><gtr:id>664FA0A0-B6F5-431F-AA4E-4D5070BAD879</gtr:id><gtr:firstName>Kholoud</gtr:firstName><gtr:surname>Porter</gtr:surname><gtr:orcidId>0000-0002-9226-6206</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A6BAEC07-E057-4F0A-933A-BF3E851B5C99"><gtr:id>A6BAEC07-E057-4F0A-933A-BF3E851B5C99</gtr:id><gtr:firstName>Abdel</gtr:firstName><gtr:otherNames>Ghayoum</gtr:otherNames><gtr:surname>Babiker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/168CFD16-EA26-4A8A-B3E6-5E11BD817F3E"><gtr:id>168CFD16-EA26-4A8A-B3E6-5E11BD817F3E</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Tyre</gtr:otherNames><gtr:surname>Dunn</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122886352"><gtr:id>34EF7216-19DE-41AD-8EA5-4C8349F7E429</gtr:id><gtr:title>Adult HIV Clinical Trials</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122886352</gtr:grantReference><gtr:abstractText>Combination antiretroviral therapy (ART) for HIV infection is highly effective, but needs to be taken life-long, has some short and long-term side effects and is expensive. This programme has several clinical trials looking at important unanswered questions. |Firstly, it is not clear exactly when is the best time to start ART. A trial called SPARTAC is looking at whether treating with ART is of benefit shortly after someone has first become infected with HIV. The START trial will examine whether people with a high CD4 count (above 500) obtain any benefit from starting ART straight away, rather than waiting until the count declines further.||There may be other ways of treating HIV infection early on that mean that conventional ART can be delayed. The HCQ-01 trial is looking at whether hydroxychloroquine, an anti-inflammatory drug may have a benefit in controlling the immune damage caused by HIV.||The class of drugs called protease inhibitors (PIs), may be able to maintain long term HIV control when used alone (traditionally they are used in combinatino with other drugs). PIVOT is a trial that will find out whether PI monotherapy is just as good as conventional triple therapy in the long-term management of HIV disease and whether it helps to cut down long-term side effects as well as costs.||The MRC EARNEST trial will investigate several novel combinations for second line therapy in Africa, to identify the best standard combination that can be used in public health rollout programmes for HIV treatment.</gtr:abstractText><gtr:technicalSummary>This programme aims to address important questions about the best time to start HIV treatment, whether there are alternative aprpoaches using anti-inflammatory drugs, and whether there are alternative strategies to reduce costs and improve long term outcomes.||There are several trials in the programme that address the optimal timing of therapy. The SPARTAC trial has randomised 366 patients with acute HIV infection to ART (12 or 48 weeks) or no ART to determine the time taken for the CD4 count to fall below 350 cells. The trial will report in 2011. The START trial will randomise 4000 patients with CD4 cell counts above 500 cells/mm3 to receive immediate ART or to have treatment deferred until the CD4 count falls below 350 cells. The trial aims to determine what benefits (if any) result from earlier treatment and to assess the health-economic issues around early ART. ||HIV leads to immune activation and increased inflammation, both of which may play a critical role in HIV pathogenesis. The HCQ-01 trial examines whether hydroxychloroquine, a cheap and well tolerated immunomodulatory drug, can decrease immune activation in ART-naive patients with CD4 cell counts above 400 cells. A decrease in immune activation may lead to slowing of disease progression, thereby delaying the timing of starting conventional ART. ||The advent of more potent individual drugs, particularly the protease inhibitors (PIs) means that combination triple therapy may no longer be needed to control HIV viral replication. The PIVOT trial will determine whether PI monotherapy is non-inferior to triple therapy over long-term follow-up, an approach that may reduce long term toxicity as well as result in substantial health economic benefits. The trial has recruited 560 patients at 50 sites across the UK, and will run until 2013. ||There is virtually no evidence from randomised controlled trials to determine the best option for second line therapy in patients who fail treatment with a standard first-line NNRTI-based combination. The Europe-Africa Research Network for Evaluation of Second-line therapy (EARNEST) Trial, will randomise 1200 patients to one of three options: lopinavir/ritonavir with 2 NRTIs (the standard of care) or lopinavir/ritonavir plus raltegravir (a new integrase inhibitor) or lopinavir/ritonavir monotherapy (after a period of induction with raltegravir). The trial will run until 2013.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>23065678</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Berkshire Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>79074CC7-2993-488B-B31E-63FDC9F136E0</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-8</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>8428EB91-899B-4F17-A171-50390A254083</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-7</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Elizabeth Hospital (Malaysia)</gtr:collaboratingOrganisation><gtr:country>Malaysia</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>421C03CA-82E6-4BEB-8965-5F31197DC331</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-31</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ibn Rochd University Hospital</gtr:collaboratingOrganisation><gtr:country>Morocco, Kingdom of</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>148F39A3-1CA7-4F8E-8ED6-92096E10015B</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-20</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Copenhagen HIV Programme (CHIP)</gtr:department><gtr:description>NEAT001/ANRS 143</gtr:description><gtr:id>ABCAE6AB-FE40-403B-BDEE-74DBD0C56207</gtr:id><gtr:impact>The first trial NEAT 001 commenced in September 2010 and recruitment of the target of 800 patients was achieved in October 2011. Follow-up was completed in September 2013, primary results were presented at the international conference on Retroviruses and Opportunistic Infections (CROI) in March 2014 and the main paper published in the Lancet in August 2014. A number of secondary analyses and substudies are being undertaken.</gtr:impact><gtr:outcomeId>76A41724D04-2</gtr:outcomeId><gtr:partnerContribution>The 3 NEAT partners in Copenhagen, France and Amsterdam constitute the remaining CTUs involved in the coordination of the NEAT001 trial across Europe. Partners have also been working on the other areas of the network outside of the clinical trial such as education and translation work.</gtr:partnerContribution><gtr:piContribution>The MRC CTU is one of 4 co-ordinating CTUs and is the Statistical centre for this collaboration. Unit senior scientists are on the Trial Steering committee and provide expertise and support on all aspects to study design and analysis. The research team at CTU were active members across all the trial management groups and coordinated the trial in a number of European countries. The MRC CTU also took the lead for the Biobank/Specimen Coordination for the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Copenhagen HIV Programme (CHIP)</gtr:department><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>7DECA2C5-2F1D-4DF0-A5C9-7C2B128223D8</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-3</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERM SC10 - US019</gtr:department><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>504EB548-9BDD-4853-A950-E14B90D774D9</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-14</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Victoria Teaching Hospital</gtr:collaboratingOrganisation><gtr:country>Gambia, Republic of the</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>4783185A-0B82-4068-9E59-8130E77CF299</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-21</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Italian National Health Service</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Istituto Superiore di Sanit? (ISS)</gtr:department><gtr:description>EARNEST</gtr:description><gtr:id>2EFD0A0A-89DD-4619-B54F-F398E335BF69</gtr:id><gtr:impact>Primary 96 week comparison of the randomised arms published in NEJM 2014.
Five conference abstracts submitted to CROI 2015.</gtr:impact><gtr:outcomeId>DvmDYtdCdkN-2</gtr:outcomeId><gtr:partnerContribution>CINECA in kind contributions towards the database, web community and website.
UCD in kind contributions in the form of support and supervision of PhD students.
Institute of Tropical Medicine supported the EARNEST Bone Mineral Density Substudy.</gtr:partnerContribution><gtr:piContribution>The Europe - Africa Research Network for Evaluation of Second-line Therapy (EARNEST) is a partnership between 14 African clinical research sites and 6 European organisations, including the MRC CTU. It was funded by the European and Developing Countries Clinical Trials Programme (EDCTP) and European national research funding agencies. The network conducted the EARNEST trial, the definitive clinical trial which aimed to indentify the best antiretroviral therapy for HIV-infected adults and adolescents who need to switch from first-line antiretroviral therapy in a resource limited setting. The trial enrolled 1277 patients from 5 African countries - Malawi, Uganda, Zimbabwe, Kenya and Zambia from April 2010 to April 2011. The first results from the trial were published in the New England Journal of Medicine in 2014 with more results informing how best to deliver second line therapy in resource limited settings to come. 

EARNEST also aimed to build capacity for conducting clinical trials in Africa through training activities related to the trial, by supporting MSc and PhD training programmes for trial staff, and by enhancing the physical infrastructure at trial sites. It has strengthened African collaborative links and communication through a programme of networking activities.

The Chief Investigator of the EARNEST trial, Prof Nick Paton, was a senior scientist at MRC CTU, and the MRC CTU team led on all trial management activities and associated training, statistical analyses and general research management. MRC CTU also organised and managed the work of local trial monitors, again building capacity, and the independent endpoint review committee which review all clinical primary and secondary endpoints.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Washington DC Va Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>INSIGHT</gtr:description><gtr:id>9647E317-333C-4C61-9BE7-32D92AC76030</gtr:id><gtr:impact>The SMART, ESPRIT, SILCAAT, STALWART and START trials. Numerous publications which have been entered in section 2.</gtr:impact><gtr:outcomeId>004D9B8D0CE-4</gtr:outcomeId><gtr:partnerContribution>The Copenhagen HIV programme, Kirby institute, sydney and the group in Washington DC are the three remaining international coordinating centres within the Network. Each partner inputs into the various network governamce committees and coordinates the studies within their region.</gtr:partnerContribution><gtr:piContribution>The MRC Clinical Trials Unit acts as one of the 4 international coordinating centres for this network. Unit senior scientists sit on the Executive Steering Committee, Scientific Steering Committee, Operational Sterring Committee and co-chair the START trial. 

The Network is active in HIV research ( the START study) and continues to recruit to the influenza studies ( FLU002, FLU003 and FLU004) and we coordinate these studies in the countires within our region.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Washington DC Va Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Institute for Clinical Research</gtr:department><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>F383DCE5-3928-45A9-B5AD-BE35A67F894E</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-4</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chelsea and Westminster Health Charity</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>St Stephen????????s AIDS Trust</gtr:department><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>D8CE8238-3D39-4D6B-8428-886DF1D398F4</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-32</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Minnesota</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>INSIGHT (International Network for Strategic Initiatives in Global HIV Trials)</gtr:description><gtr:id>F5452BE4-4E1A-4B1A-8BE4-5A9CFE3C081C</gtr:id><gtr:impact>results of several clinical trials such as SMART and START and publications and presentations on observational Influenza studies FLU002, FLU003 and FLU004</gtr:impact><gtr:outcomeId>56d9d221dbead6.65668667-1</gtr:outcomeId><gtr:partnerContribution>see above</gtr:partnerContribution><gtr:piContribution>Partner in this International Network for Strategic Initiatives in Global HIV Trials since 2006. Since then INSIGHT's scope has broadened and now the network also conducts several influenza studies. Our mission is to define optimal strategies for the management of HIV and other infectious diseases through a global clinical research network. INSIGHT conducts studies worldwide with each of the 4 coordinating centres managing different regions around the world. involved in all trial management issues and have representation on scientific, operational and executive steering committees for the group.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Mary's Hospital, London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>DAFC8C55-9CDC-4811-8DA6-D0E832A72834</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-25</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bordeaux</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>NEAT001/ANRS 143</gtr:description><gtr:id>B10FD71A-B61B-4BE7-B008-510BD80DB890</gtr:id><gtr:impact>The first trial NEAT 001 commenced in September 2010 and recruitment of the target of 800 patients was achieved in October 2011. Follow-up was completed in September 2013, primary results were presented at the international conference on Retroviruses and Opportunistic Infections (CROI) in March 2014 and the main paper published in the Lancet in August 2014. A number of secondary analyses and substudies are being undertaken.</gtr:impact><gtr:outcomeId>76A41724D04-3</gtr:outcomeId><gtr:partnerContribution>The 3 NEAT partners in Copenhagen, France and Amsterdam constitute the remaining CTUs involved in the coordination of the NEAT001 trial across Europe. Partners have also been working on the other areas of the network outside of the clinical trial such as education and translation work.</gtr:partnerContribution><gtr:piContribution>The MRC CTU is one of 4 co-ordinating CTUs and is the Statistical centre for this collaboration. Unit senior scientists are on the Trial Steering committee and provide expertise and support on all aspects to study design and analysis. The research team at CTU were active members across all the trial management groups and coordinated the trial in a number of European countries. The MRC CTU also took the lead for the Biobank/Specimen Coordination for the trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>SPARTAC</gtr:description><gtr:id>606F041B-1268-4877-B54C-5E39E5A39E05</gtr:id><gtr:impact>Trial completed and main manuscript published in the New England Journal of Medicine in Jan 2013 and a several of secondary publications in 2014 added to section 2</gtr:impact><gtr:outcomeId>HBj54S4Luze-1</gtr:outcomeId><gtr:partnerContribution>ICSTM: Clinical oversight, finance, coordination of oversight committees and virology
University of New South Wales: Coordination of the trial in Australian sites
MRC Uganda:Coordination of the trial in Ugandan sites
University of Oxford: Immunology</gtr:partnerContribution><gtr:piContribution>Design, management and analysis of SPARTAC a multicentre randomised controlled trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medical School</gtr:department><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>2B8A69FB-F05D-49E9-B333-E8B821113474</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-22</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Italian National Health Service</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Istituto Superiore di Sanit? (ISS)</gtr:department><gtr:description>NEAT001/ANRS 143</gtr:description><gtr:id>FC320C15-8409-4192-ACAA-C75C3DF990A6</gtr:id><gtr:impact>The first trial NEAT 001 commenced in September 2010 and recruitment of the target of 800 patients was achieved in October 2011. Follow-up was completed in September 2013, primary results were presented at the international conference on Retroviruses and Opportunistic Infections (CROI) in March 2014 and the main paper published in the Lancet in August 2014. A number of secondary analyses and substudies are being undertaken.</gtr:impact><gtr:outcomeId>76A41724D04-1</gtr:outcomeId><gtr:partnerContribution>The 3 NEAT partners in Copenhagen, France and Amsterdam constitute the remaining CTUs involved in the coordination of the NEAT001 trial across Europe. Partners have also been working on the other areas of the network outside of the clinical trial such as education and translation work.</gtr:partnerContribution><gtr:piContribution>The MRC CTU is one of 4 co-ordinating CTUs and is the Statistical centre for this collaboration. Unit senior scientists are on the Trial Steering committee and provide expertise and support on all aspects to study design and analysis. The research team at CTU were active members across all the trial management groups and coordinated the trial in a number of European countries. The MRC CTU also took the lead for the Biobank/Specimen Coordination for the trial.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Bern</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>6D2C3050-901A-4A25-AE99-E3BBE55483B6</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-17</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Sussex County Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>17C82859-A1F2-4D06-8A22-86C4979979FB</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-6</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St Thomas' Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>24C0BE0F-0192-4866-8A90-67EAF4D2731C</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-24</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Southmead Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>DF875430-EC4D-4EEF-B159-4BB722E95103</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-29</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC/UVRI Uganda Research Unit on AIDS</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>SPARTAC</gtr:description><gtr:id>1F4A28F5-FF7B-4BEE-9932-8AB745A047DD</gtr:id><gtr:impact>Trial completed and main manuscript published in the New England Journal of Medicine in Jan 2013 and a several of secondary publications in 2014 added to section 2</gtr:impact><gtr:outcomeId>HBj54S4Luze-3</gtr:outcomeId><gtr:partnerContribution>ICSTM: Clinical oversight, finance, coordination of oversight committees and virology
University of New South Wales: Coordination of the trial in Australian sites
MRC Uganda:Coordination of the trial in Ugandan sites
University of Oxford: Immunology</gtr:partnerContribution><gtr:piContribution>Design, management and analysis of SPARTAC a multicentre randomised controlled trial</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UK Community Advisory Board UKCAB</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PIVOT</gtr:description><gtr:id>F2972C4E-06C0-4BA8-A779-D6EC1FFF19B8</gtr:id><gtr:impact>Main findings were presented at the Conference On Retroviruses And Opportunistic Infections (CROI) 2014.</gtr:impact><gtr:outcomeId>AvVxfze6w9B-2</gtr:outcomeId><gtr:partnerContribution>Community organisations have been involved in PIVOT from the beginning, contributing not only with protocol development and implementation but also promoting the study on community media and offering possible participants information about the strategy being tested. Positive involvement of advocacy groups definitively helped the study to reach diverse communities affected by HIV to make the represented in the study population. The African Eye Trust, an NGO which supports African Communities affected by HIV in the UK was extremely important in introducing the study and offering impartial information about PI monotherapy to their target population. In addition the UK-CAB, a national network for community HIV treatment advocates, is also involved in PIVOT with direct representation in both the Trial Steering and the Independent Data Monitoring Committees.</gtr:partnerContribution><gtr:piContribution>PIVOT is the largest RCT on HIV treatment ever performed in the UK which recruited 587 patients from a network of 43 sites across the country. This network includes not only large HIV clinics linked to academic institutions traditionally involved on clinical research but also smaller centres with little experience on clinical research. The PIVOT network covers most of England (and a centre in Scotland), and therefore its study population is more diverse than in most HIV trials. The PIVOT trial has offered an important opportunity for building capacity and training to sites not previously involved in clinical research at this scale. This has been facilitated by the financial support centres have received from their comprehensive local research networks (CLRN) as PIVOT was one of the first studies adopted into the NIHR Clinical Research Network Portfolio.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Athens</gtr:collaboratingOrganisation><gtr:country>Greece, Hellenic Republic</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>67E05E0D-C696-4EB8-AA0C-BBFA842CD925</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-13</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HCQ</gtr:description><gtr:id>97AAB3DD-F6C4-4729-B1C9-854B92326FCE</gtr:id><gtr:impact>Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy : A Randomized Controlled Trial 
Nicholas I. Paton, MD, FRCP; Ruth L. Goodall, PhD; David T. Dunn, PhD; Samuel Franzen, BSc; Yolanda Collaco-Moraes, PhD; Brian G. Gazzard, MD, FRCP; Ian G. Williams, MA, FRCP; Martin J. Fisher, FRCP; Alan Winston, MD, MRCP; Julie Fox, MD, MRCP; Chloe Orkin, MRCP; Elbushra A. Herieka, MRCOG; Jonathan G. Ainsworth, FRCP; Frank A. Post, PhD, FCP(SA); Mark Wansbrough-Jones, FRCP; Peter Kelleher, PhD, MRCPath; for the Hydroxychloroquine Trial Team 
JAMA. 2012;308(4):353-361. doi:10.1001/jama.2012.6936

Effects of hydroxychloroquine on immune activation in ART- na&amp;iuml;ve patients: a 48-week randomised, double-blind, placebo-controlled trial
N Paton for the Hydroxychloroquine Trial Team 
6th International AIDS Society Conference, July 2011 - Rome, Italy: Poster presentation: MOPE269 

14th Annual conference of the British HIV Association (BHIVA) Belfast July 2008
MRC CTU oral session research to establish optimal long-term treatment strategies 

HIV treatment Bulletin Volume 9 Number 5/6 May /June 2008
Can hydroxychloroquine decrease immune activation in asymptomatic patients. 

The African Eye voice May 2009-July 2009 
Immune Activation: the other side of HIV Laura Waters 

Plus/ve/ your health your choice Vol 79 September 2008
Immune Activation: the other side of HIV Laura Waters 

UK Advisory Board Meeting (UK-CAB) 
Study presented for discussion at summer 2008 meeting</gtr:impact><gtr:outcomeId>VqmFCFcDGyF-1</gtr:outcomeId><gtr:partnerContribution>The primary end point of the study were change in CD8 T-cell activation at week 48 compared to baseline (as shown by a percentage of the cells expressing CD38+ and HLA-DR+).

with secondary endpoints looking at efficacy and safety outcome measures. The immunology assays were performed centrally at the Chelsea and Westminster Immunology laboratory under the supervision of Dr Peter Kelleher.</gtr:partnerContribution><gtr:piContribution>An Randomised clinical trial to evaluate the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients.

The MRC was sponsor of the trial and all responsibilities delegated to the MRC clinical trials unit. The trial team ran all aspects of the trial from regulatory and ethical approval to statistical analysis and writing of the main publication.

MRC Clinical Trials Unit have supported the trial to its conclusion. This is because the recruitment period took longer than expected and resulted in patient follow-up continuing beyond the duration of the Wellcome grant. 

Sites found it harder to recruit to the trial than expected, mainly because patients who have asymptomatic HIV disease have been reluctant to start any medication. In addition these stable patients are seen only a couple of times a year in the clinic. Some of the inclusion criteria have been relaxed where possible (without compromising patient safety) and this improved recruitment. The number of participating sites was been expanded within the UK. This was not extended to sites outside the UK as the grant proposal to Wellcome Trust was not successful.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Copenhagen HIV Programme (CHIP)</gtr:department><gtr:description>INSIGHT (International Network for Strategic Initiatives in Global HIV Trials)</gtr:description><gtr:id>D501BEAA-3623-44BE-A9E2-EB5E1F22D239</gtr:id><gtr:impact>results of several clinical trials such as SMART and START and publications and presentations on observational Influenza studies FLU002, FLU003 and FLU004</gtr:impact><gtr:outcomeId>56d9d221dbead6.65668667-4</gtr:outcomeId><gtr:partnerContribution>see above</gtr:partnerContribution><gtr:piContribution>Partner in this International Network for Strategic Initiatives in Global HIV Trials since 2006. Since then INSIGHT's scope has broadened and now the network also conducts several influenza studies. Our mission is to define optimal strategies for the management of HIV and other infectious diseases through a global clinical research network. INSIGHT conducts studies worldwide with each of the 4 coordinating centres managing different regions around the world. involved in all trial management issues and have representation on scientific, operational and executive steering committees for the group.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>San Raffaele Hospital</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>8E77CF2C-26C4-4A1D-A312-9F10EA29DDAB</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-18</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Manchester General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>26234CF2-D145-46BD-B707-3A8A6E252B19</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-28</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Joint Clinical Research Center, Kampala</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>CFA520D8-3E59-48B1-BE1C-C95C9FC8F5D0</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-15</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Gloucestershire Royal Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>0A212650-3896-4FB5-8E72-E86AE35C43BA</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-10</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cineca</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>EARNEST</gtr:description><gtr:id>AA63E9C3-BC5E-45F4-9BB1-8D5B0907AB5C</gtr:id><gtr:impact>Primary 96 week comparison of the randomised arms published in NEJM 2014.
Five conference abstracts submitted to CROI 2015.</gtr:impact><gtr:outcomeId>DvmDYtdCdkN-1</gtr:outcomeId><gtr:partnerContribution>CINECA in kind contributions towards the database, web community and website.
UCD in kind contributions in the form of support and supervision of PhD students.
Institute of Tropical Medicine supported the EARNEST Bone Mineral Density Substudy.</gtr:partnerContribution><gtr:piContribution>The Europe - Africa Research Network for Evaluation of Second-line Therapy (EARNEST) is a partnership between 14 African clinical research sites and 6 European organisations, including the MRC CTU. It was funded by the European and Developing Countries Clinical Trials Programme (EDCTP) and European national research funding agencies. The network conducted the EARNEST trial, the definitive clinical trial which aimed to indentify the best antiretroviral therapy for HIV-infected adults and adolescents who need to switch from first-line antiretroviral therapy in a resource limited setting. The trial enrolled 1277 patients from 5 African countries - Malawi, Uganda, Zimbabwe, Kenya and Zambia from April 2010 to April 2011. The first results from the trial were published in the New England Journal of Medicine in 2014 with more results informing how best to deliver second line therapy in resource limited settings to come. 

EARNEST also aimed to build capacity for conducting clinical trials in Africa through training activities related to the trial, by supporting MSc and PhD training programmes for trial staff, and by enhancing the physical infrastructure at trial sites. It has strengthened African collaborative links and communication through a programme of networking activities.

The Chief Investigator of the EARNEST trial, Prof Nick Paton, was a senior scientist at MRC CTU, and the MRC CTU team led on all trial management activities and associated training, statistical analyses and general research management. MRC CTU also organised and managed the work of local trial monitors, again building capacity, and the independent endpoint review committee which review all clinical primary and secondary endpoints.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Medicine</gtr:department><gtr:description>SPARTAC</gtr:description><gtr:id>61A45716-DFFE-4F27-A982-7EFC4741AE46</gtr:id><gtr:impact>Trial completed and main manuscript published in the New England Journal of Medicine in Jan 2013 and a several of secondary publications in 2014 added to section 2</gtr:impact><gtr:outcomeId>HBj54S4Luze-4</gtr:outcomeId><gtr:partnerContribution>ICSTM: Clinical oversight, finance, coordination of oversight committees and virology
University of New South Wales: Coordination of the trial in Australian sites
MRC Uganda:Coordination of the trial in Ugandan sites
University of Oxford: Immunology</gtr:partnerContribution><gtr:piContribution>Design, management and analysis of SPARTAC a multicentre randomised controlled trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of New South Wales</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Kirby Institute</gtr:department><gtr:description>SPARTAC</gtr:description><gtr:id>3B59D450-1F39-4781-9611-851A88233651</gtr:id><gtr:impact>Trial completed and main manuscript published in the New England Journal of Medicine in Jan 2013 and a several of secondary publications in 2014 added to section 2</gtr:impact><gtr:outcomeId>HBj54S4Luze-2</gtr:outcomeId><gtr:partnerContribution>ICSTM: Clinical oversight, finance, coordination of oversight committees and virology
University of New South Wales: Coordination of the trial in Australian sites
MRC Uganda:Coordination of the trial in Ugandan sites
University of Oxford: Immunology</gtr:partnerContribution><gtr:piContribution>Design, management and analysis of SPARTAC a multicentre randomised controlled trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Minnesota</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>C4237E00-76CB-4407-93A2-967266466B55</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-1</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Tropical Medicine Antwerp</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>EARNEST</gtr:description><gtr:id>F2156546-9E38-45F3-A57F-19D6EECBA792</gtr:id><gtr:impact>Primary 96 week comparison of the randomised arms published in NEJM 2014.
Five conference abstracts submitted to CROI 2015.</gtr:impact><gtr:outcomeId>DvmDYtdCdkN-4</gtr:outcomeId><gtr:partnerContribution>CINECA in kind contributions towards the database, web community and website.
UCD in kind contributions in the form of support and supervision of PhD students.
Institute of Tropical Medicine supported the EARNEST Bone Mineral Density Substudy.</gtr:partnerContribution><gtr:piContribution>The Europe - Africa Research Network for Evaluation of Second-line Therapy (EARNEST) is a partnership between 14 African clinical research sites and 6 European organisations, including the MRC CTU. It was funded by the European and Developing Countries Clinical Trials Programme (EDCTP) and European national research funding agencies. The network conducted the EARNEST trial, the definitive clinical trial which aimed to indentify the best antiretroviral therapy for HIV-infected adults and adolescents who need to switch from first-line antiretroviral therapy in a resource limited setting. The trial enrolled 1277 patients from 5 African countries - Malawi, Uganda, Zimbabwe, Kenya and Zambia from April 2010 to April 2011. The first results from the trial were published in the New England Journal of Medicine in 2014 with more results informing how best to deliver second line therapy in resource limited settings to come. 

EARNEST also aimed to build capacity for conducting clinical trials in Africa through training activities related to the trial, by supporting MSc and PhD training programmes for trial staff, and by enhancing the physical infrastructure at trial sites. It has strengthened African collaborative links and communication through a programme of networking activities.

The Chief Investigator of the EARNEST trial, Prof Nick Paton, was a senior scientist at MRC CTU, and the MRC CTU team led on all trial management activities and associated training, statistical analyses and general research management. MRC CTU also organised and managed the work of local trial monitors, again building capacity, and the independent endpoint review committee which review all clinical primary and secondary endpoints.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>EARNEST</gtr:description><gtr:id>4666C3BC-E972-4794-8BC6-FA701EB2A21E</gtr:id><gtr:impact>Primary 96 week comparison of the randomised arms published in NEJM 2014.
Five conference abstracts submitted to CROI 2015.</gtr:impact><gtr:outcomeId>DvmDYtdCdkN-3</gtr:outcomeId><gtr:partnerContribution>CINECA in kind contributions towards the database, web community and website.
UCD in kind contributions in the form of support and supervision of PhD students.
Institute of Tropical Medicine supported the EARNEST Bone Mineral Density Substudy.</gtr:partnerContribution><gtr:piContribution>The Europe - Africa Research Network for Evaluation of Second-line Therapy (EARNEST) is a partnership between 14 African clinical research sites and 6 European organisations, including the MRC CTU. It was funded by the European and Developing Countries Clinical Trials Programme (EDCTP) and European national research funding agencies. The network conducted the EARNEST trial, the definitive clinical trial which aimed to indentify the best antiretroviral therapy for HIV-infected adults and adolescents who need to switch from first-line antiretroviral therapy in a resource limited setting. The trial enrolled 1277 patients from 5 African countries - Malawi, Uganda, Zimbabwe, Kenya and Zambia from April 2010 to April 2011. The first results from the trial were published in the New England Journal of Medicine in 2014 with more results informing how best to deliver second line therapy in resource limited settings to come. 

EARNEST also aimed to build capacity for conducting clinical trials in Africa through training activities related to the trial, by supporting MSc and PhD training programmes for trial staff, and by enhancing the physical infrastructure at trial sites. It has strengthened African collaborative links and communication through a programme of networking activities.

The Chief Investigator of the EARNEST trial, Prof Nick Paton, was a senior scientist at MRC CTU, and the MRC CTU team led on all trial management activities and associated training, statistical analyses and general research management. MRC CTU also organised and managed the work of local trial monitors, again building capacity, and the independent endpoint review committee which review all clinical primary and secondary endpoints.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Copenhagen HIV Programme (CHIP)</gtr:department><gtr:description>INSIGHT</gtr:description><gtr:id>F96BA87C-6C3C-47D6-A4E8-20D7A656241B</gtr:id><gtr:impact>The SMART, ESPRIT, SILCAAT, STALWART and START trials. Numerous publications which have been entered in section 2.</gtr:impact><gtr:outcomeId>004D9B8D0CE-2</gtr:outcomeId><gtr:partnerContribution>The Copenhagen HIV programme, Kirby institute, sydney and the group in Washington DC are the three remaining international coordinating centres within the Network. Each partner inputs into the various network governamce committees and coordinates the studies within their region.</gtr:partnerContribution><gtr:piContribution>The MRC Clinical Trials Unit acts as one of the 4 international coordinating centres for this network. Unit senior scientists sit on the Executive Steering Committee, Scientific Steering Committee, Operational Sterring Committee and co-chair the START trial. 

The Network is active in HIV research ( the START study) and continues to recruit to the influenza studies ( FLU002, FLU003 and FLU004) and we coordinate these studies in the countires within our region.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Minnesota</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>INSIGHT</gtr:description><gtr:id>D6BAA430-F5D8-4249-9DCD-DC0714C6BC2B</gtr:id><gtr:impact>The SMART, ESPRIT, SILCAAT, STALWART and START trials. Numerous publications which have been entered in section 2.</gtr:impact><gtr:outcomeId>004D9B8D0CE-1</gtr:outcomeId><gtr:partnerContribution>The Copenhagen HIV programme, Kirby institute, sydney and the group in Washington DC are the three remaining international coordinating centres within the Network. Each partner inputs into the various network governamce committees and coordinates the studies within their region.</gtr:partnerContribution><gtr:piContribution>The MRC Clinical Trials Unit acts as one of the 4 international coordinating centres for this network. Unit senior scientists sit on the Executive Steering Committee, Scientific Steering Committee, Operational Sterring Committee and co-chair the START trial. 

The Network is active in HIV research ( the START study) and continues to recruit to the influenza studies ( FLU002, FLU003 and FLU004) and we coordinate these studies in the countires within our region.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amsterdam Institute for Global Health and Development (AIGHD)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>NEAT001/ANRS 143</gtr:description><gtr:id>DF18C39B-54DE-4815-A4BF-54E59B8C7CD3</gtr:id><gtr:impact>The first trial NEAT 001 commenced in September 2010 and recruitment of the target of 800 patients was achieved in October 2011. Follow-up was completed in September 2013, primary results were presented at the international conference on Retroviruses and Opportunistic Infections (CROI) in March 2014 and the main paper published in the Lancet in August 2014. A number of secondary analyses and substudies are being undertaken.</gtr:impact><gtr:outcomeId>76A41724D04-4</gtr:outcomeId><gtr:partnerContribution>The 3 NEAT partners in Copenhagen, France and Amsterdam constitute the remaining CTUs involved in the coordination of the NEAT001 trial across Europe. Partners have also been working on the other areas of the network outside of the clinical trial such as education and translation work.</gtr:partnerContribution><gtr:piContribution>The MRC CTU is one of 4 co-ordinating CTUs and is the Statistical centre for this collaboration. Unit senior scientists are on the Trial Steering committee and provide expertise and support on all aspects to study design and analysis. The research team at CTU were active members across all the trial management groups and coordinated the trial in a number of European countries. The MRC CTU also took the lead for the Biobank/Specimen Coordination for the trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birmingham Heartlands Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>3F508E28-855D-40F1-A9EC-441FE37E17BF</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-27</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC/UVRI Uganda Research Unit on AIDS</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>C5925180-8887-4FAD-B9AC-5219A35A36FE</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-16</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Bournemouth Hospital</gtr:department><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>62BE6F6C-629B-403A-B92A-5B6E61A86CDF</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-9</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Hallamshire Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>AD48701B-F950-4A86-9CF9-CB6ACFFCE5DA</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-11</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:department>School of Medicine and Medical Science</gtr:department><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>C4B8E21B-7F47-4FFF-BFE9-9560C18B97F1</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-19</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of New South Wales</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>389988B6-065D-435F-98AD-DFFC1DDE8FF7</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-2</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>21FF3EB6-AC33-4E66-8BEB-1BBB5A2EB52A</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-26</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Washington DC Va Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Institute for Clinical Research</gtr:department><gtr:description>INSIGHT (International Network for Strategic Initiatives in Global HIV Trials)</gtr:description><gtr:id>89BFB435-05FD-45A3-A77E-EDE3AF8F33E1</gtr:id><gtr:impact>results of several clinical trials such as SMART and START and publications and presentations on observational Influenza studies FLU002, FLU003 and FLU004</gtr:impact><gtr:outcomeId>56d9d221dbead6.65668667-3</gtr:outcomeId><gtr:partnerContribution>see above</gtr:partnerContribution><gtr:piContribution>Partner in this International Network for Strategic Initiatives in Global HIV Trials since 2006. Since then INSIGHT's scope has broadened and now the network also conducts several influenza studies. Our mission is to define optimal strategies for the management of HIV and other infectious diseases through a global clinical research network. INSIGHT conducts studies worldwide with each of the 4 coordinating centres managing different regions around the world. involved in all trial management issues and have representation on scientific, operational and executive steering committees for the group.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>African Eye Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PIVOT</gtr:description><gtr:id>C43D459C-BC2B-44E0-A8A5-AACF04719AF1</gtr:id><gtr:impact>Main findings were presented at the Conference On Retroviruses And Opportunistic Infections (CROI) 2014.</gtr:impact><gtr:outcomeId>AvVxfze6w9B-1</gtr:outcomeId><gtr:partnerContribution>Community organisations have been involved in PIVOT from the beginning, contributing not only with protocol development and implementation but also promoting the study on community media and offering possible participants information about the strategy being tested. Positive involvement of advocacy groups definitively helped the study to reach diverse communities affected by HIV to make the represented in the study population. The African Eye Trust, an NGO which supports African Communities affected by HIV in the UK was extremely important in introducing the study and offering impartial information about PI monotherapy to their target population. In addition the UK-CAB, a national network for community HIV treatment advocates, is also involved in PIVOT with direct representation in both the Trial Steering and the Independent Data Monitoring Committees.</gtr:partnerContribution><gtr:piContribution>PIVOT is the largest RCT on HIV treatment ever performed in the UK which recruited 587 patients from a network of 43 sites across the country. This network includes not only large HIV clinics linked to academic institutions traditionally involved on clinical research but also smaller centres with little experience on clinical research. The PIVOT network covers most of England (and a centre in Scotland), and therefore its study population is more diverse than in most HIV trials. The PIVOT trial has offered an important opportunity for building capacity and training to sites not previously involved in clinical research at this scale. This has been facilitated by the financial support centres have received from their comprehensive local research networks (CLRN) as PIVOT was one of the first studies adopted into the NIHR Clinical Research Network Portfolio.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barts Health NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>20EF503F-37DA-4E91-8499-C98CCE378828</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-5</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Universitario La Paz</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>EARNEST</gtr:description><gtr:id>00B2960D-E422-406E-B2E9-C1A722F88D69</gtr:id><gtr:impact>Primary 96 week comparison of the randomised arms published in NEJM 2014.
Five conference abstracts submitted to CROI 2015.</gtr:impact><gtr:outcomeId>DvmDYtdCdkN-5</gtr:outcomeId><gtr:partnerContribution>CINECA in kind contributions towards the database, web community and website.
UCD in kind contributions in the form of support and supervision of PhD students.
Institute of Tropical Medicine supported the EARNEST Bone Mineral Density Substudy.</gtr:partnerContribution><gtr:piContribution>The Europe - Africa Research Network for Evaluation of Second-line Therapy (EARNEST) is a partnership between 14 African clinical research sites and 6 European organisations, including the MRC CTU. It was funded by the European and Developing Countries Clinical Trials Programme (EDCTP) and European national research funding agencies. The network conducted the EARNEST trial, the definitive clinical trial which aimed to indentify the best antiretroviral therapy for HIV-infected adults and adolescents who need to switch from first-line antiretroviral therapy in a resource limited setting. The trial enrolled 1277 patients from 5 African countries - Malawi, Uganda, Zimbabwe, Kenya and Zambia from April 2010 to April 2011. The first results from the trial were published in the New England Journal of Medicine in 2014 with more results informing how best to deliver second line therapy in resource limited settings to come. 

EARNEST also aimed to build capacity for conducting clinical trials in Africa through training activities related to the trial, by supporting MSc and PhD training programmes for trial staff, and by enhancing the physical infrastructure at trial sites. It has strengthened African collaborative links and communication through a programme of networking activities.

The Chief Investigator of the EARNEST trial, Prof Nick Paton, was a senior scientist at MRC CTU, and the MRC CTU team led on all trial management activities and associated training, statistical analyses and general research management. MRC CTU also organised and managed the work of local trial monitors, again building capacity, and the independent endpoint review committee which review all clinical primary and secondary endpoints.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of New South Wales</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Kirby Institute</gtr:department><gtr:description>INSIGHT</gtr:description><gtr:id>7CDD9EF8-B52E-4186-A072-23B6A6036BBD</gtr:id><gtr:impact>The SMART, ESPRIT, SILCAAT, STALWART and START trials. Numerous publications which have been entered in section 2.</gtr:impact><gtr:outcomeId>004D9B8D0CE-3</gtr:outcomeId><gtr:partnerContribution>The Copenhagen HIV programme, Kirby institute, sydney and the group in Washington DC are the three remaining international coordinating centres within the Network. Each partner inputs into the various network governamce committees and coordinates the studies within their region.</gtr:partnerContribution><gtr:piContribution>The MRC Clinical Trials Unit acts as one of the 4 international coordinating centres for this network. Unit senior scientists sit on the Executive Steering Committee, Scientific Steering Committee, Operational Sterring Committee and co-chair the START trial. 

The Network is active in HIV research ( the START study) and continues to recruit to the influenza studies ( FLU002, FLU003 and FLU004) and we coordinate these studies in the countires within our region.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of New South Wales</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>INSIGHT (International Network for Strategic Initiatives in Global HIV Trials)</gtr:description><gtr:id>942BE1A9-9CB0-41EB-ADA2-1236FC9D3EDE</gtr:id><gtr:impact>results of several clinical trials such as SMART and START and publications and presentations on observational Influenza studies FLU002, FLU003 and FLU004</gtr:impact><gtr:outcomeId>56d9d221dbead6.65668667-2</gtr:outcomeId><gtr:partnerContribution>see above</gtr:partnerContribution><gtr:piContribution>Partner in this International Network for Strategic Initiatives in Global HIV Trials since 2006. Since then INSIGHT's scope has broadened and now the network also conducts several influenza studies. Our mission is to define optimal strategies for the management of HIV and other infectious diseases through a global clinical research network. INSIGHT conducts studies worldwide with each of the 4 coordinating centres managing different regions around the world. involved in all trial management issues and have representation on scientific, operational and executive steering committees for the group.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>James Cook University Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Strategic Timing of AntiRetroviral Treatment (START) Study</gtr:description><gtr:id>2D4BBC9E-694A-40C1-9203-D738E1669668</gtr:id><gtr:impact>publications
presentations</gtr:impact><gtr:outcomeId>56d9ceb2b9e509.24782352-12</gtr:outcomeId><gtr:partnerContribution>Sponsor- University of Minnesota

three other international coordination groups which manage the study in the other countries of the world
University of New South Wales
Copenhagen HIV Programme (CHIP)
The Institute for Clinical Research at the Veterans Affairs Medical Center 

work with University of Athens, INSERM SC10 and University of Bern to oversee management of sites in Greece, France and Switzerland and directly with the other 26 participating sites form UK , Ireland, Morocco, Italy and Uganda 

work with University of Athens, SC10 and University of Bern to coordinate participating clinical sites in Greece, France and Switzerland
XX clinical sites , 20 in UK , 1 in Ireland , 1 in Morocco and 2 in Uganda</gtr:partnerContribution><gtr:piContribution>Trial management, safety reporting, monitoring etc in the sites with in the UK, Ireland, Uganda, Morocco, Greece, Italy , France and Switzerland
participate in the protocol team, quality management groups and substudy teams across the study and lead at CTU is co-chair for the study.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>246000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Individual project grant</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>96B66A21-76A2-4CC2-92CD-E4134D8B349B</gtr:id><gtr:outcomeId>DDECBE1E9480</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>872801</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>EC FP6 Collaborative Projects</gtr:department><gtr:description>NEAT (for NEAT001)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>D89E5EA6-137B-453C-A753-656CDAEFF06E</gtr:id><gtr:outcomeId>dn3xefrkbbK</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16153712</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>INSIGHT</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>1DBFDB8B-C7D1-44AD-858B-8EB174BA9C4F</gtr:id><gtr:outcomeId>bNr62gt1aMz</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1928677</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>HTA</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>3780F2D1-AFB3-4694-9C34-E1187E9DB36F</gtr:id><gtr:outcomeId>5C5BB28D5490</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4200000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>EDCTP</gtr:description><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>89DFAB3F-B687-4546-83A1-C3C15679B188</gtr:id><gtr:outcomeId>D16EC29BA9A0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HIV treatment guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents</gtr:guidelineTitle><gtr:id>7627BD06-2DB3-4A0C-8CAB-EDF5E4A1EF45</gtr:id><gtr:impact>The findings of the SMART trial have changed the way that HIV is practised internationally. Not only did the trial prove that treatment interruption was harmful, but the trial also demonstrated the importance of previously unrecognised complications of HIV early in the course of disease e.g. cardiovascular events. THis has lead to a change in international guidelines towards earlier treatment.</gtr:impact><gtr:outcomeId>139BF5A34DD</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8431F5EB-577D-4850-9045-841A4407EB13</gtr:id><gtr:title>Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b09662fc6e54df360346c345f98ea177"><gtr:id>b09662fc6e54df360346c345f98ea177</gtr:id><gtr:otherNames>Lynfield R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5464cf1a3cf5f0.63230970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97B21B29-D2B2-4C8A-BC36-828CF3EE0FDD</gtr:id><gtr:title>Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56e0534513d105.05300308</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47ADEFE5-AAEC-42BB-9CAE-DE29382D884A</gtr:id><gtr:title>Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69ee4e6d872e105b9c2c2dbaf4eaa52b"><gtr:id>69ee4e6d872e105b9c2c2dbaf4eaa52b</gtr:id><gtr:otherNames>Wand H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>098FC756B7D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71C72F50-59B8-4AA4-8BB2-06112D81646D</gtr:id><gtr:title>Short-course antiretroviral therapy in primary HIV infection.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce76d6881f4431b5a0c18f099ab1deb0"><gtr:id>ce76d6881f4431b5a0c18f099ab1deb0</gtr:id><gtr:otherNames>SPARTAC Trial Investigators</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_15451_21_23323897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E80D0F91-9F45-470F-94EC-5A898078ACDD</gtr:id><gtr:title>Clustering based on adherence data.</gtr:title><gtr:parentPublicationTitle>Epidemiologic perspectives &amp; innovations : EP+I</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/207f4372d9394a7f2f77d3925ca02563"><gtr:id>207f4372d9394a7f2f77d3925ca02563</gtr:id><gtr:otherNames>Kiwuwa-Muyingo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-5573</gtr:issn><gtr:outcomeId>pm_15451_21_21385451</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A27B07C6-053C-471C-B688-DDB67C4E9C40</gtr:id><gtr:title>Anaemia and blood transfusion in African children presenting to hospital with severe febrile illness.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a95726c6f6fe2073a4b03b81f5d7def1"><gtr:id>a95726c6f6fe2073a4b03b81f5d7def1</gtr:id><gtr:otherNames>Kiguli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>56e053418ed993.68509756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F175F59B-5C0F-4FB6-B86B-AA05871184B9</gtr:id><gtr:title>Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants.</gtr:title><gtr:parentPublicationTitle>HIV clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d773ff714e9544d2822cf735539faf9"><gtr:id>3d773ff714e9544d2822cf735539faf9</gtr:id><gtr:otherNames>Pett SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1528-4336</gtr:issn><gtr:outcomeId>nY7Rk5RGz7b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D985F5FB-973B-41F6-80EA-7B877D0807EC</gtr:id><gtr:title>Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1f966a23825be14e7e40185309919ec"><gtr:id>a1f966a23825be14e7e40185309919ec</gtr:id><gtr:otherNames>Dwyer DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>pm_15451_21_21757105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B7A4C8B-D19E-46E5-9D93-A47E9499822F</gtr:id><gtr:title>Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/120c5e360c11621a0ad5309caabc5cb7"><gtr:id>120c5e360c11621a0ad5309caabc5cb7</gtr:id><gtr:otherNames>Boulware DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>sP9WUyrZiW4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63D87979-372F-45CC-B021-6E419142069C</gtr:id><gtr:title>Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209dc6a04f521377c3617f5457c4355c"><gtr:id>209dc6a04f521377c3617f5457c4355c</gtr:id><gtr:otherNames>Munderi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>fiGtbCXh9V9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EF439A1-6474-4E7B-86C4-34D8A2B10ACE</gtr:id><gtr:title>Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c14764bcf85e05fc0e882e893936f5e"><gtr:id>5c14764bcf85e05fc0e882e893936f5e</gtr:id><gtr:otherNames>Wright EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>CMiRUhtvjLH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4344654-1743-44D8-9F89-0EAA8CAF4299</gtr:id><gtr:title>Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy</gtr:title><gtr:parentPublicationTitle>AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56ecc24f1457bf44eaaa5dec325d1328"><gtr:id>56ecc24f1457bf44eaaa5dec325d1328</gtr:id><gtr:otherNames>Arenas-Pinto A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a351659e6ceb0.86804253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8FC1833-A08C-4F8B-B745-C995FC35E79B</gtr:id><gtr:title>Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a3d43f723a2016ce57399ac5c1728c3"><gtr:id>6a3d43f723a2016ce57399ac5c1728c3</gtr:id><gtr:otherNames>Andrade BB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_15451_21_23335804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91D38119-D1EB-4589-B6C9-500D2E920747</gtr:id><gtr:title>Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/892a5db9bd0105eed9902e792884e372"><gtr:id>892a5db9bd0105eed9902e792884e372</gtr:id><gtr:otherNames>Neuhaus J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>Vndm2mwJXv2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CAB2EC5-ABD9-465B-AAC6-938F74D4C5BB</gtr:id><gtr:title>Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/051cf62d6d905f0304eb0c4d1af8ba2e"><gtr:id>051cf62d6d905f0304eb0c4d1af8ba2e</gtr:id><gtr:otherNames>Lyagoba F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>V1mS6ZCorAD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87E32C2C-20A6-4523-B9C1-C32E44D4B655</gtr:id><gtr:title>Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7f5f4c8349da86b35e3575dc9bd508e"><gtr:id>c7f5f4c8349da86b35e3575dc9bd508e</gtr:id><gtr:otherNames>Medina Lara A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15451_21_22545079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C591997-33F5-492C-A53D-E605C86B5B1B</gtr:id><gtr:title>HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b97465a4b060ca541e5d1714b00b1ca3"><gtr:id>b97465a4b060ca541e5d1714b00b1ca3</gtr:id><gtr:otherNames>Baker JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>nAyAY6cg82P</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>287612D9-5D43-4165-BAC1-E3185BCA3257</gtr:id><gtr:title>Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect.</gtr:title><gtr:parentPublicationTitle>Journal of neurovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5eb677ac90c24dd0cfe0c415652db9b"><gtr:id>a5eb677ac90c24dd0cfe0c415652db9b</gtr:id><gtr:otherNames>Grund B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1355-0284</gtr:issn><gtr:outcomeId>pm_15451_21_23943468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8E30B7B-EF4D-4AA7-8EF2-CF1F4E39B720</gtr:id><gtr:title>Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>545b58b734be94.68056917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1EA7623-11A4-4498-9860-F752536AA851</gtr:id><gtr:title>Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c14764bcf85e05fc0e882e893936f5e"><gtr:id>5c14764bcf85e05fc0e882e893936f5e</gtr:id><gtr:otherNames>Wright EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56dd995002b301.92122796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>442ADA88-9B1B-4D61-98EC-9AA103632E05</gtr:id><gtr:title>Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.</gtr:title><gtr:parentPublicationTitle>Journal of the American Heart Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be8aa26f1ec9562467cef9b7769e67a5"><gtr:id>be8aa26f1ec9562467cef9b7769e67a5</gtr:id><gtr:otherNames>Nordell AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2047-9980</gtr:issn><gtr:outcomeId>5464cf8da930e4.14975479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A924208-B40F-4D9E-ADAB-EEE127E10E10</gtr:id><gtr:title>Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count&amp;gt;or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/709a06852421493b285416b4b3c4c4c6"><gtr:id>709a06852421493b285416b4b3c4c4c6</gtr:id><gtr:otherNames>ESPRIT Research Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>esm8UUCmise</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8998CDC-F680-43FD-BB63-6B915CFC7034</gtr:id><gtr:title>Mean Corpuscular Volume as a Marker for Adherence to Zidovudine-Containing Therapy in HIV-Infected Adults.</gtr:title><gtr:parentPublicationTitle>The open AIDS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d2135da75179e9dc72734d2eb63329a"><gtr:id>1d2135da75179e9dc72734d2eb63329a</gtr:id><gtr:otherNames>Mugisha JO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_15451_21_22715353</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C9524D9-D585-4EEC-9D72-B14050A187F3</gtr:id><gtr:title>Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f348d127ad0dfafe68772dadfbf883"><gtr:id>d1f348d127ad0dfafe68772dadfbf883</gtr:id><gtr:otherNames>Walker AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>TDMH748dWFS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1626FD6E-023F-4394-A6D7-F18801B2DB67</gtr:id><gtr:title>Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e231ea3b1743df950897bdf7f0b50814"><gtr:id>e231ea3b1743df950897bdf7f0b50814</gtr:id><gtr:otherNames>Dore GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>PhGTXEUdrwA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6438B5CD-0C4F-4900-9CB5-BA499AD5F793</gtr:id><gtr:title>Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b97465a4b060ca541e5d1714b00b1ca3"><gtr:id>b97465a4b060ca541e5d1714b00b1ca3</gtr:id><gtr:otherNames>Baker JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56d9c14e7dcb00.96802548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1696255C-04DD-468D-8F82-7A7FC37E90B0</gtr:id><gtr:title>Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/300bcd2c5353d921955a498aa2888782"><gtr:id>300bcd2c5353d921955a498aa2888782</gtr:id><gtr:otherNames>DART Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>JfFYK8BbmWz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82EBFC2C-3859-47F5-8A53-EC45350C07A9</gtr:id><gtr:title>The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aa64ae486428fd99ca0a334b2bef924"><gtr:id>6aa64ae486428fd99ca0a334b2bef924</gtr:id><gtr:otherNames>Inshaw J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e05344349dc3.11335252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C55D85E5-35C5-486F-8BD0-AF766AD95787</gtr:id><gtr:title>Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4070c90b48bbc5f45f31500b299bfac4"><gtr:id>4070c90b48bbc5f45f31500b299bfac4</gtr:id><gtr:otherNames>Vogel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>SMKkjZVZ8wn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3CC8854-4EEE-40AA-B6A9-A6754A0FAA97</gtr:id><gtr:title>Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/107dbc3d05069dfb970adce0d5ed3470"><gtr:id>107dbc3d05069dfb970adce0d5ed3470</gtr:id><gtr:otherNames>Geffen N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56dd979d889723.98400771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58653EFB-EA83-4315-A4E0-69A5ED449056</gtr:id><gtr:title>Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfea2b9b73ed105e38dc7df00abf225d"><gtr:id>bfea2b9b73ed105e38dc7df00abf225d</gtr:id><gtr:otherNames>Rotger M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_15451_21_23532479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EFB2DF8-8546-4513-B90A-3496C18AFBCC</gtr:id><gtr:title>CD4+count-guided interruption of antiretroviral treatment</gtr:title><gtr:parentPublicationTitle>NEW ENGLAND JOURNAL OF MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59a77d5556ebae0ef4781da109f630fe"><gtr:id>59a77d5556ebae0ef4781da109f630fe</gtr:id><gtr:otherNames>El-Sadr W. M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5a360f15698410.65689145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB4B379E-0663-4A26-BDB4-AA4795056CC4</gtr:id><gtr:title>Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ace442991d80db8655f18f8d0589d70"><gtr:id>2ace442991d80db8655f18f8d0589d70</gtr:id><gtr:otherNames>Denning E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56e054e3e040e0.76398107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39810E43-B674-4F26-BCB4-558C2B6C2089</gtr:id><gtr:title>Inflammation, coagulation and cardiovascular disease in HIV-infected individuals.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90d69989c8a7ee34f9bc879caac71c3f"><gtr:id>90d69989c8a7ee34f9bc879caac71c3f</gtr:id><gtr:otherNames>Duprez DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15451_21_22970224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>230570C1-61D9-41D8-8443-FB37DDB2F63A</gtr:id><gtr:title>CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells &amp;lt;200 Cell/?L: The DART Trial STI Substudy.</gtr:title><gtr:parentPublicationTitle>AIDS research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40c4ac075a6de4679b80ef146ceae513"><gtr:id>40c4ac075a6de4679b80ef146ceae513</gtr:id><gtr:otherNames>Serwanga J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2090-1240</gtr:issn><gtr:outcomeId>jW6YiUGVfRw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1C21715-5B49-4BD4-A452-2A1CCE8A8BF3</gtr:id><gtr:title>Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/253d8694e84088177c481d62432672a1"><gtr:id>253d8694e84088177c481d62432672a1</gtr:id><gtr:otherNames>Pace C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>nChowamKauH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C63DEC7E-7E47-4027-BCF3-5FA25C19DC72</gtr:id><gtr:title>Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e0edbd1eda4dac3b4621c7f78a21da8"><gtr:id>5e0edbd1eda4dac3b4621c7f78a21da8</gtr:id><gtr:otherNames>Tavel JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>j7MaXVZ5b8H</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86986555-2722-404B-95B3-4309B95D6D98</gtr:id><gtr:title>The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28abda6ba97bec2efbad45aa45ec857b"><gtr:id>28abda6ba97bec2efbad45aa45ec857b</gtr:id><gtr:otherNames>Martinez E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>M6AfVAKiRWx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F88920A8-F703-4E42-931E-BD62EC586929</gtr:id><gtr:title>Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96888be17bf947367e44907c170ce926"><gtr:id>96888be17bf947367e44907c170ce926</gtr:id><gtr:otherNames>Kikaire B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>202F32CCB7A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3C92EAE-FFA9-42C9-9535-3110E4C97E30</gtr:id><gtr:title>Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dc4a8166f3451f21dd1278fc669e5e5"><gtr:id>1dc4a8166f3451f21dd1278fc669e5e5</gtr:id><gtr:otherNames>Soliman EZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>fRd5LYgHVWs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>408E7259-E74F-45B5-A87A-B6E3141E6165</gtr:id><gtr:title>Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1132c254e977729416cdedf9f3f7428"><gtr:id>c1132c254e977729416cdedf9f3f7428</gtr:id><gtr:otherNames>Muyingo SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>PwgXT5z9Yzg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C70ABE5C-94EA-4148-98C6-827335C49769</gtr:id><gtr:title>Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f409e6effa963165e88c95c6b2a649eb"><gtr:id>f409e6effa963165e88c95c6b2a649eb</gtr:id><gtr:otherNames>Reid A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>UGt1TZDxX6X</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEE704D7-0599-476A-AFC4-8B12D47E5207</gtr:id><gtr:title>Modelling the evolution and spread of HIV immune escape mutants.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4733c7e44c2264f342e6713e0e09b0be"><gtr:id>4733c7e44c2264f342e6713e0e09b0be</gtr:id><gtr:otherNames>Fryer HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_15451_21_21124991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9040F41-B495-47E4-95D6-1234E6C81F17</gtr:id><gtr:title>Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9f8b490c0ae563537366df960a54b14"><gtr:id>a9f8b490c0ae563537366df960a54b14</gtr:id><gtr:otherNames>Neaton JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>RGuEhhJxBUN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B445F3AB-6014-4CFA-974A-FD6E2D8C3354</gtr:id><gtr:title>Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6044d1bc57187297b6d30db6d3decedd"><gtr:id>6044d1bc57187297b6d30db6d3decedd</gtr:id><gtr:otherNames>Rodger AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56dd98f2e5a774.63447065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>286019A9-49AF-4307-A21E-D2129EE58C04</gtr:id><gtr:title>Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2829bf40f2ead8322cd3febe3403c183"><gtr:id>2829bf40f2ead8322cd3febe3403c183</gtr:id><gtr:otherNames>Achhra AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>fA9jvZJjUrQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DEE3002-88CB-4D1D-AECA-C4C01A7D622B</gtr:id><gtr:title>The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/207f4372d9394a7f2f77d3925ca02563"><gtr:id>207f4372d9394a7f2f77d3925ca02563</gtr:id><gtr:otherNames>Kiwuwa-Muyingo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>pm_15451_21_22463596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>786C8A99-DA9D-4457-BFAE-50525BF2B4EF</gtr:id><gtr:title>Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a36c594481c9e5162bca5d1edaf25ac0"><gtr:id>a36c594481c9e5162bca5d1edaf25ac0</gtr:id><gtr:otherNames>Kityo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>aJzYJMcvmSd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92FE0BA6-0D5C-48F1-9A7D-D8C4408E75AE</gtr:id><gtr:title>Empirical evaluation of the need for 'on-going consent' in clinical research.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89314afe407ab0f79cf15f9d0f030d85"><gtr:id>89314afe407ab0f79cf15f9d0f030d85</gtr:id><gtr:otherNames>Smith W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>AaXbzTLEpj9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D13C8D44-3B9A-4B19-9918-70273D9AB476</gtr:id><gtr:title>Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e970e5adfdc099a2041de941fcda3ef4"><gtr:id>e970e5adfdc099a2041de941fcda3ef4</gtr:id><gtr:otherNames>Fox Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>SBdDefjWnDA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ADFD3B0-F00A-440D-B80A-B64AF839F0C7</gtr:id><gtr:title>CD4+ count-guided interruption of antiretroviral treatment.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff3733554effd78bf8b96731c4d283c0"><gtr:id>ff3733554effd78bf8b96731c4d283c0</gtr:id><gtr:otherNames>Strategies for Management of Antiretroviral Therapy (SMART) Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pyNUeZJEqNC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70A0F4D1-F88D-4319-8A35-7C56DE3C3640</gtr:id><gtr:title>Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3154809a0f2cd5682a8bfbf13cb271e1"><gtr:id>3154809a0f2cd5682a8bfbf13cb271e1</gtr:id><gtr:otherNames>Matthews GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56d9c3a06ccf25.44550061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B6B7F1D-111A-41B5-8EF1-F60B4CDFAE4A</gtr:id><gtr:title>Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5cc7c98c8ac1a0cc6c63cc1a5480087"><gtr:id>f5cc7c98c8ac1a0cc6c63cc1a5480087</gtr:id><gtr:otherNames>Lampe FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>X69MeAUqDGV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D46CB11E-2861-40DA-A3A4-152DFCDD1A99</gtr:id><gtr:title>Factors associated with D-dimer levels in HIV-infected individuals.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6260a796dc8f5e490c4fd0383c77b53"><gtr:id>a6260a796dc8f5e490c4fd0383c77b53</gtr:id><gtr:otherNames>Borges AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5464cd9c179ba4.37842161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7C11B92-8950-48FF-8AE6-0D01734F8956</gtr:id><gtr:title>INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f478c468a1f3d730340b9c725a3e8fbf"><gtr:id>f478c468a1f3d730340b9c725a3e8fbf</gtr:id><gtr:otherNames>INSIGHT FLU005 IVIG Pilot Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>56e053463d6e35.38982074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDBA8A7F-C7BE-4CB1-BBCE-CE794F80FDF1</gtr:id><gtr:title>Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff3733554effd78bf8b96731c4d283c0"><gtr:id>ff3733554effd78bf8b96731c4d283c0</gtr:id><gtr:otherNames>Strategies for Management of Antiretroviral Therapy (SMART) Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>tsNKWFujNcs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB9F56C2-5C68-4CC4-9AF7-60502693EBEB</gtr:id><gtr:title>Structured observations reveal slow HIV-1 CTL escape.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47b3a1a51c3002305d7f4b6e5412f23a"><gtr:id>47b3a1a51c3002305d7f4b6e5412f23a</gtr:id><gtr:otherNames>Roberts HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>56e0534156a621.91375476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F493BA2D-9A64-42CE-AD33-DE32F67A0269</gtr:id><gtr:title>Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a115fb22ae8b5eb1d761afe50087d24"><gtr:id>9a115fb22ae8b5eb1d761afe50087d24</gtr:id><gtr:otherNames>McCormick AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>UGSLtzNKThX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6C32879-83D0-43BE-9BEE-9FDC6D45C597</gtr:id><gtr:title>Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2829bf40f2ead8322cd3febe3403c183"><gtr:id>2829bf40f2ead8322cd3febe3403c183</gtr:id><gtr:otherNames>Achhra AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15451_21_22614887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F02C085B-46E2-4089-938F-BE55578B6C02</gtr:id><gtr:title>Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dc4a8166f3451f21dd1278fc669e5e5"><gtr:id>1dc4a8166f3451f21dd1278fc669e5e5</gtr:id><gtr:otherNames>Soliman EZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56dd9920b55b50.43445064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C64B07B2-CDB4-41C8-8BF0-60681B2EE250</gtr:id><gtr:title>Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/892a5db9bd0105eed9902e792884e372"><gtr:id>892a5db9bd0105eed9902e792884e372</gtr:id><gtr:otherNames>Neuhaus J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>tC69XiNN1qk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C25E4A0-FF81-4E0B-A35A-491C8C45D628</gtr:id><gtr:title>The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c36f1492c05290516a79c33fee1ea4b"><gtr:id>5c36f1492c05290516a79c33fee1ea4b</gtr:id><gtr:otherNames>Mocroft A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>PCBmBTMRwdU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E6F30F4-2979-48A2-8731-45247BE52A70</gtr:id><gtr:title>Platelet count kinetics following interruption of antiretroviral treatment.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48c35b48f7fd974ce410d640785c9861"><gtr:id>48c35b48f7fd974ce410d640785c9861</gtr:id><gtr:otherNames>Zetterberg E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15451_21_23018440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>269264B3-EB75-46FF-82A7-510178D4F380</gtr:id><gtr:title>Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8616d2352dbea8b78e93784790b11c4"><gtr:id>c8616d2352dbea8b78e93784790b11c4</gtr:id><gtr:otherNames>Sharma S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56d9c44e2542d6.17940514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54A2BAD7-3CEB-4B5E-9995-D99EA045143F</gtr:id><gtr:title>The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95e0fa3832bdd90396f651925a145639"><gtr:id>95e0fa3832bdd90396f651925a145639</gtr:id><gtr:otherNames>Burman WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>GraGDwFneVf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2877CAB-FBD6-49EF-B2EC-38CF27804674</gtr:id><gtr:title>Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a8bde31d95ec586098b2322368ff463"><gtr:id>5a8bde31d95ec586098b2322368ff463</gtr:id><gtr:otherNames>Ndembi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pnoK6FKKii9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC3CF42B-E96E-4549-9433-D5B1C5DE8A4A</gtr:id><gtr:title>Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41a877171348ee069ec46fdee8578b69"><gtr:id>41a877171348ee069ec46fdee8578b69</gtr:id><gtr:otherNames>Law MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56dd9886db1a91.00267482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B52150CB-414E-4538-9AF1-FE405454E59E</gtr:id><gtr:title>Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a35586be0a5b78e8a4231529ab32ca2"><gtr:id>1a35586be0a5b78e8a4231529ab32ca2</gtr:id><gtr:otherNames>O'Connor JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_15451_21_23204161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F8E6D30-5F0F-4E2A-A3C8-E299CE32292D</gtr:id><gtr:title>A virological benefit from an induction/maintenance strategy: the Forte trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3941afdcfdc2b0638d643b9faffc4de6"><gtr:id>3941afdcfdc2b0638d643b9faffc4de6</gtr:id><gtr:otherNames>Asboe D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>2052A0CD2B2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58210CB3-3F8B-4ED9-B4D5-FFDA8B9A6ACB</gtr:id><gtr:title>Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f76496409ebd723eb37f62919a49eeb"><gtr:id>4f76496409ebd723eb37f62919a49eeb</gtr:id><gtr:otherNames>Gilks CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_15451_21_22814125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>907D7513-7F07-4D0F-8C2E-82DED6395EEC</gtr:id><gtr:title>Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5396838a64e07f0e26ca612ba419eddb"><gtr:id>5396838a64e07f0e26ca612ba419eddb</gtr:id><gtr:otherNames>Thornhill J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>56e05345d4d401.83265205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3434A713-AED8-4118-8191-4AF04A301B2A</gtr:id><gtr:title>Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.</gtr:title><gtr:parentPublicationTitle>HIV clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9654d2860d955eb2eb0308a6934be87f"><gtr:id>9654d2860d955eb2eb0308a6934be87f</gtr:id><gtr:otherNames>Lifson AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1528-4336</gtr:issn><gtr:outcomeId>Xce6RFV6HVa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F5F39E1-40E9-4BDF-BC46-0369BF5145EE</gtr:id><gtr:title>Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6749b7fb8b90ae10766864fe00a3159f"><gtr:id>6749b7fb8b90ae10766864fe00a3159f</gtr:id><gtr:otherNames>Martin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>pm_15451_21_22720101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8366D253-8711-4C9A-83E4-57093B77478A</gtr:id><gtr:title>Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15451_21_22952756</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDCE95B5-6FB2-4B27-88E3-09BCA8484CD2</gtr:id><gtr:title>Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37c07563452dc912586fa690391871c5"><gtr:id>37c07563452dc912586fa690391871c5</gtr:id><gtr:otherNames>Tedaldi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>jTNgvqFovcG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24B93022-94D9-43CB-851F-762A6FC55F73</gtr:id><gtr:title>HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation.</gtr:title><gtr:parentPublicationTitle>Journal of the American Heart Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b97465a4b060ca541e5d1714b00b1ca3"><gtr:id>b97465a4b060ca541e5d1714b00b1ca3</gtr:id><gtr:otherNames>Baker JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2047-9980</gtr:issn><gtr:outcomeId>pm_15451_21_23896681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD69328E-6980-4E9C-B56D-600E3C92A474</gtr:id><gtr:title>Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14356e9699c962c762a4c6e584b266bc"><gtr:id>14356e9699c962c762a4c6e584b266bc</gtr:id><gtr:otherNames>Gibb DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_15451_21_22615543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B18CBBC4-AD45-4423-BEAD-C7F438ABFDED</gtr:id><gtr:title>Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/965ed1c909e709949b7c722ebf462a31"><gtr:id>965ed1c909e709949b7c722ebf462a31</gtr:id><gtr:otherNames>Bjerk SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15451_21_23457535</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA875D95-3127-4486-BD7A-568E7654C1D6</gtr:id><gtr:title>Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) Trial.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dc4a8166f3451f21dd1278fc669e5e5"><gtr:id>1dc4a8166f3451f21dd1278fc669e5e5</gtr:id><gtr:otherNames>Soliman EZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_15451_21_23471611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AEC3A67-A0FE-4BD7-A9E8-E396A3CC88E4</gtr:id><gtr:title>Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection.</gtr:title><gtr:parentPublicationTitle>The American journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5de3c2020bc7ff6ef903eb03a012ee09"><gtr:id>5de3c2020bc7ff6ef903eb03a012ee09</gtr:id><gtr:otherNames>Gupta M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9149</gtr:issn><gtr:outcomeId>pm_15451_21_23276469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBAE3002-329A-48D6-A3B3-B4F327574358</gtr:id><gtr:title>Limitations of proposed novel trial design.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/619570981e5c1fd56fbbfd0fa3f49528"><gtr:id>619570981e5c1fd56fbbfd0fa3f49528</gtr:id><gtr:otherNames>Dunn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15451_21_22954759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>370DA7BE-3CFE-481F-99C9-6E534314C12D</gtr:id><gtr:title>Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/866322dc913095117b6a766204c1cd4f"><gtr:id>866322dc913095117b6a766204c1cd4f</gtr:id><gtr:otherNames>Lucas GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5464cf1a044685.41257556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF9F015D-10E9-4E58-AFF6-3357E125E048</gtr:id><gtr:title>Re: &amp;quot;Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts&amp;quot;.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9654d2860d955eb2eb0308a6934be87f"><gtr:id>9654d2860d955eb2eb0308a6934be87f</gtr:id><gtr:otherNames>Lifson AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>5464cf19d05974.66223903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A76C2227-5493-4529-9D79-215784D803E3</gtr:id><gtr:title>Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08821a48c1621dc6d5c6100dad4defc4"><gtr:id>08821a48c1621dc6d5c6100dad4defc4</gtr:id><gtr:otherNames>Raffi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56e05340f3f220.77693809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4DA0404-1CBE-478F-847D-297604172C92</gtr:id><gtr:title>Benefits and burdens of participation in a longitudinal clinical trial.</gtr:title><gtr:parentPublicationTitle>Journal of empirical research on human research ethics : JERHRE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3dfe1305fbeed470f8b14d61032ff15"><gtr:id>e3dfe1305fbeed470f8b14d61032ff15</gtr:id><gtr:otherNames>Lazovski J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1556-2646</gtr:issn><gtr:outcomeId>ftA2N11P2Dw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FA9067A-722C-4489-8299-8BDB4D03DBBA</gtr:id><gtr:title>Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a409def97754c3f9b5001e11f39b5b7d"><gtr:id>a409def97754c3f9b5001e11f39b5b7d</gtr:id><gtr:otherNames>Babiker AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>pm_15451_21_22547421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>687CD4E1-C34B-46E4-9B3A-7C63A7B68C0E</gtr:id><gtr:title>Interruption of antiretroviral therapy is associated with increased plasma cystatin C.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c36f1492c05290516a79c33fee1ea4b"><gtr:id>5c36f1492c05290516a79c33fee1ea4b</gtr:id><gtr:otherNames>Mocroft A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>cboNoKJpBRB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58276DDA-E503-48C6-BB37-EE44C620D815</gtr:id><gtr:title>Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c33c411ca28c0a937d2f7e2ccf2775a7"><gtr:id>c33c411ca28c0a937d2f7e2ccf2775a7</gtr:id><gtr:otherNames>Gordin FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>TPpF3WmgsdB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79CFEAF8-F0F8-4E65-B10E-4FB2179550BC</gtr:id><gtr:title>Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>Eju45asqVAu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35CB6031-041D-48B8-A252-11A81499B2C8</gtr:id><gtr:title>Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc2e7d73a6004930162e36bfcf84e5b8"><gtr:id>cc2e7d73a6004930162e36bfcf84e5b8</gtr:id><gtr:otherNames>Burman W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>p9PtMJfQTS9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BDFE002-476E-4418-BD58-C0A392BA0916</gtr:id><gtr:title>Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6589a6edec43e949cf7efb511a358e84"><gtr:id>6589a6edec43e949cf7efb511a358e84</gtr:id><gtr:otherNames>Samri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>E227259F1DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC4E2F3D-2BFA-4A0C-B976-71FE5807258D</gtr:id><gtr:title>Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af41ba5a001caff9cfc7754a2e495376"><gtr:id>af41ba5a001caff9cfc7754a2e495376</gtr:id><gtr:otherNames>Dart Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>gbyfbbdfVLX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89342D42-27C7-4D27-936D-733B0087A50E</gtr:id><gtr:title>Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/204b3fba8c82b0d72f21535fc6b103d3"><gtr:id>204b3fba8c82b0d72f21535fc6b103d3</gtr:id><gtr:otherNames>Ssali F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>KNwdrt5FVA8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7459CF5-3086-449F-A2D4-784060E393BD</gtr:id><gtr:title>The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d40f983c26b14cc725a711fb9036e4d"><gtr:id>5d40f983c26b14cc725a711fb9036e4d</gtr:id><gtr:otherNames>Arenas-Pinto A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>biVQZ5Vyp8H</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0294B54F-BAAA-4E52-9E28-EAB2F5B0DF9E</gtr:id><gtr:title>Lipoprotein particle subclasses, cardiovascular disease and HIV infection.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90d69989c8a7ee34f9bc879caac71c3f"><gtr:id>90d69989c8a7ee34f9bc879caac71c3f</gtr:id><gtr:otherNames>Duprez DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn><gtr:outcomeId>MaMJ9n1LR4s</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73D1503C-507D-462A-956A-221B97B88F80</gtr:id><gtr:title>Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ef8197ce4283cc301844715589ea6be"><gtr:id>0ef8197ce4283cc301844715589ea6be</gtr:id><gtr:otherNames>SMART Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>JX8nHN6wbyg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F115F96-8DB7-44DB-A61E-5176A71DE934</gtr:id><gtr:title>Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ef8197ce4283cc301844715589ea6be"><gtr:id>0ef8197ce4283cc301844715589ea6be</gtr:id><gtr:otherNames>SMART Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn><gtr:outcomeId>stu3E8Wv4DT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C07D6178-F039-4F81-9D77-5F77F8505D2D</gtr:id><gtr:title>Determination of the underlying cause of death in three multicenter international HIV clinical trials.</gtr:title><gtr:parentPublicationTitle>HIV clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9654d2860d955eb2eb0308a6934be87f"><gtr:id>9654d2860d955eb2eb0308a6934be87f</gtr:id><gtr:otherNames>Lifson AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1528-4336</gtr:issn><gtr:outcomeId>U6zjZuj1VJr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0093F5D9-6B2B-4005-9A8B-0949697983CD</gtr:id><gtr:title>Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6044d1bc57187297b6d30db6d3decedd"><gtr:id>6044d1bc57187297b6d30db6d3decedd</gtr:id><gtr:otherNames>Rodger AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15451_21_23698063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91C17DB0-9B6F-458B-89DD-A3D5ABAF4EC7</gtr:id><gtr:title>Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95b54794c6ede234f1a44d2601c1c2e0"><gtr:id>95b54794c6ede234f1a44d2601c1c2e0</gtr:id><gtr:otherNames>Holodniy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15451_21_21483491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB517BAD-F26E-47F7-8998-E0D3DDB8FF09</gtr:id><gtr:title>When to start antiretroviral therapy: the need for an evidence base during early HIV infection.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/706e64244ff2700b01e93feba0d8fc36"><gtr:id>706e64244ff2700b01e93feba0d8fc36</gtr:id><gtr:otherNames>Lundgren JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>pm_15451_21_23767777</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AED20E72-0C14-43A2-9426-49F63BECC27E</gtr:id><gtr:title>Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2ddd1cf25081f18695f73762e7092b4"><gtr:id>c2ddd1cf25081f18695f73762e7092b4</gtr:id><gtr:otherNames>Strategies for Management of Anti-Retroviral Therapy/INSIGHT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>BKSxzcPSVo6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBD4C60A-4B7D-4E59-A801-31FACE5731CD</gtr:id><gtr:title>HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/934ccb890f8b3d4435bbe06cfa0daeeb"><gtr:id>934ccb890f8b3d4435bbe06cfa0daeeb</gtr:id><gtr:otherNames>Frater J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>545b58b75b07a3.88995236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A2D306C-FF69-4AE1-BBC2-62AB3E5E40C4</gtr:id><gtr:title>Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff3733554effd78bf8b96731c4d283c0"><gtr:id>ff3733554effd78bf8b96731c4d283c0</gtr:id><gtr:otherNames>Strategies for Management of Antiretroviral Therapy (SMART) Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>EQ21danHvF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77B3B319-440C-4C6C-915B-42407C25A50E</gtr:id><gtr:title>Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d79163d962792ba2bf0866235386883"><gtr:id>1d79163d962792ba2bf0866235386883</gtr:id><gtr:otherNames>Kuller LH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>PvxWHC1mDun</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D922C3F7-583B-4B0B-BD9E-3E155168B4D2</gtr:id><gtr:title>HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91820a5125b1e7783f9e579697f40998"><gtr:id>91820a5125b1e7783f9e579697f40998</gtr:id><gtr:otherNames>Duda A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>Y4WCWjZbbt4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C961EC9-481F-4B93-B0BB-B3ED00F38F8A</gtr:id><gtr:title>Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d105be070a3190725488c10ec8251c9c"><gtr:id>d105be070a3190725488c10ec8251c9c</gtr:id><gtr:otherNames>Lange CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>56e05341b5a3c3.34115263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD494990-DC73-4551-91E9-236CA2BFC26A</gtr:id><gtr:title>Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study.</gtr:title><gtr:parentPublicationTitle>Journal of electrocardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e77831b3f518f88d775fda5068f9be7"><gtr:id>5e77831b3f518f88d775fda5068f9be7</gtr:id><gtr:otherNames>Dawood FZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-0736</gtr:issn><gtr:outcomeId>5464cea46f69c5.37214718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>480DBD27-BEA3-4B63-A32E-7C52A3D938C0</gtr:id><gtr:title>Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c36f1492c05290516a79c33fee1ea4b"><gtr:id>5c36f1492c05290516a79c33fee1ea4b</gtr:id><gtr:otherNames>Mocroft A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>hSmDPHqV8ge</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C639BB74-32FC-4673-9B2B-2C2AADB3E4F7</gtr:id><gtr:title>Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3356afd9c4597930603d2627f4a11ec8"><gtr:id>3356afd9c4597930603d2627f4a11ec8</gtr:id><gtr:otherNames>Grarup J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56d9c25ce60cb2.44074444</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1C94541-C02C-4FFD-9325-E6FB24612B97</gtr:id><gtr:title>Plasma levels of soluble CD14 independently predict mortality in HIV infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1aae56645e688dcedbff4e69cd4ed653"><gtr:id>1aae56645e688dcedbff4e69cd4ed653</gtr:id><gtr:otherNames>Sandler NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>CnvhjfD3oqX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF20DA8B-0B08-4410-9B7F-02D702D5AB4E</gtr:id><gtr:title>Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcef94eb14418f3c4ff6a66b0f29de49"><gtr:id>bcef94eb14418f3c4ff6a66b0f29de49</gtr:id><gtr:otherNames>INSIGHT START Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>56e05344735498.52073283</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB0A7659-3D3B-4C10-8A76-5154C0256E02</gtr:id><gtr:title>Haemoglobin and anaemia in the SMART study.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c36f1492c05290516a79c33fee1ea4b"><gtr:id>5c36f1492c05290516a79c33fee1ea4b</gtr:id><gtr:otherNames>Mocroft A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>GBkQFnTEaBV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>906B7CE7-7139-4BA6-80EF-96DF2D9EE6EA</gtr:id><gtr:title>Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eecf9ece12c8122b37c9ddd7ae1c75b0"><gtr:id>eecf9ece12c8122b37c9ddd7ae1c75b0</gtr:id><gtr:otherNames>Borges ?H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15451_21_23945504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2513F43E-BE3A-402F-B245-0FA85F0F6F04</gtr:id><gtr:title>An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffadb08aae12c5867ce7c13b7fc78833"><gtr:id>ffadb08aae12c5867ce7c13b7fc78833</gtr:id><gtr:otherNames>Olson AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56e054e37932b4.68077626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1FD9BFA-6747-4508-885D-C8552B547746</gtr:id><gtr:title>Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc171515ba5fd88e399ec7ec90cac0eb"><gtr:id>cc171515ba5fd88e399ec7ec90cac0eb</gtr:id><gtr:otherNames>Yager N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15451_21_23095315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7C465C5-B1E2-4C9F-8880-217D319FA4C5</gtr:id><gtr:title>Neurocognitive function in HIV infected patients on antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>jU7bRy4cLaY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8395F7BC-6574-4176-99FD-E9849A4E71C7</gtr:id><gtr:title>Long-term effects of intermittent IL-2 in HIV infection: extended follow-up of the INSIGHT STALWART Study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fee4353e5000fcc9841f3954682bfaca"><gtr:id>fee4353e5000fcc9841f3954682bfaca</gtr:id><gtr:otherNames>Markowitz N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15451_21_23082173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12331750-97F0-4ACC-B083-4EA45038B461</gtr:id><gtr:title>The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56e05342338a04.35458031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18EC8949-B8CB-43BA-B9EA-85602E893E64</gtr:id><gtr:title>Visceral and subcutaneous adiposity measurements in adults: influence of measurement site.</gtr:title><gtr:parentPublicationTitle>Obesity (Silver Spring, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3a990d184360692607bb72b6dbab83d"><gtr:id>a3a990d184360692607bb72b6dbab83d</gtr:id><gtr:otherNames>Ellis KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1930-7381</gtr:issn><gtr:outcomeId>MxEySz7Scnq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B7AEDDC-66AB-49DC-84A6-20FCFC2C22D9</gtr:id><gtr:title>Asymptomatic myocardial ischaemia in HIV-infected adults.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cba5f699b7a3ce461fdf862f3e576e71"><gtr:id>cba5f699b7a3ce461fdf862f3e576e71</gtr:id><gtr:otherNames>Carr A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>haUc6udEFiJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70A339B5-E2BE-4560-9432-5DF1FADEF19C</gtr:id><gtr:title>Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>jqsMC2vs5gA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACBC8A1D-C176-4B81-9705-817D0A6C6E91</gtr:id><gtr:title>Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b97465a4b060ca541e5d1714b00b1ca3"><gtr:id>b97465a4b060ca541e5d1714b00b1ca3</gtr:id><gtr:otherNames>Baker JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15451_21_21857489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E21ECC9B-82AB-4E0D-B38F-2BFEE2164A71</gtr:id><gtr:title>Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/209dc6a04f521377c3617f5457c4355c"><gtr:id>209dc6a04f521377c3617f5457c4355c</gtr:id><gtr:otherNames>Munderi P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>H953Q1cM2TN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3360917-8047-46E4-B1EC-39487962DE57</gtr:id><gtr:title>Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee63ba2643977ff7a38eab60ade1b9ef"><gtr:id>ee63ba2643977ff7a38eab60ade1b9ef</gtr:id><gtr:otherNames>Peters L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1386-6532</gtr:issn><gtr:outcomeId>5464cf8dceeb45.43056727</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DED064D-8BAA-4611-B207-9737CAF8B9D9</gtr:id><gtr:title>Relative risk of death in the SMART study</gtr:title><gtr:parentPublicationTitle>The Lancet Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5eb677ac90c24dd0cfe0c415652db9b"><gtr:id>a5eb677ac90c24dd0cfe0c415652db9b</gtr:id><gtr:otherNames>Grund B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>VhP38RGbryq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68D45C22-2758-4965-9D13-5C6BB837FD1D</gtr:id><gtr:title>Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3417d4ce8ff7e6e00ba6e34e64293c2b"><gtr:id>3417d4ce8ff7e6e00ba6e34e64293c2b</gtr:id><gtr:otherNames>DART Virology Group and Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>G7YZH2zNDKf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA4D746C-EAC0-4D28-90FA-9722B977653C</gtr:id><gtr:title>Immunological biomarkers predict HIV-1 viral rebound after treatment interruption.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8ec98240adbc03a6bc8db72fed0b1d8"><gtr:id>d8ec98240adbc03a6bc8db72fed0b1d8</gtr:id><gtr:otherNames>Hurst J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56e053459552f8.48671467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE7720E8-D802-4D7D-97AC-29EB4509A282</gtr:id><gtr:title>Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d773ff714e9544d2822cf735539faf9"><gtr:id>3d773ff714e9544d2822cf735539faf9</gtr:id><gtr:otherNames>Pett SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>ARMuCriHrmx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3743E877-33EB-45D0-92FD-64D0BBC725E3</gtr:id><gtr:title>Pulmonary function in an international sample of HIV-positive, treatment-na&amp;iuml;ve adults with CD4 counts &amp;gt; 500 cells/?L: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b38232e0e4a6d53cc9cce153be6d6947"><gtr:id>b38232e0e4a6d53cc9cce153be6d6947</gtr:id><gtr:otherNames>Kunisaki KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56dd984f58fb88.21076157</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>834C510E-6ED3-4118-92F0-F028439C4280</gtr:id><gtr:title>Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7dff8560ad26aa65e434108b4aed7c8"><gtr:id>a7dff8560ad26aa65e434108b4aed7c8</gtr:id><gtr:otherNames>Paton NI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>pm_15451_21_22820788</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A672F4C7-D248-4DA4-9485-17707BB1009C</gtr:id><gtr:title>CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bd1fcf241d14b6c36fb9cd9e645ed02"><gtr:id>2bd1fcf241d14b6c36fb9cd9e645ed02</gtr:id><gtr:otherNames>Arduino RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>LeRApSSLyod</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30781286-BADE-465A-9F5B-B52A08CCDD76</gtr:id><gtr:title>Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.</gtr:title><gtr:parentPublicationTitle>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9520a1a85604ce622ba002dcd054ee46"><gtr:id>9520a1a85604ce622ba002dcd054ee46</gtr:id><gtr:otherNames>Hoy J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0884-0431</gtr:issn><gtr:outcomeId>pm_15451_21_23299909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A9B8491-9DFA-4D2B-B017-12AF580266E7</gtr:id><gtr:title>Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial.</gtr:title><gtr:parentPublicationTitle>American journal of public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9654d2860d955eb2eb0308a6934be87f"><gtr:id>9654d2860d955eb2eb0308a6934be87f</gtr:id><gtr:otherNames>Lifson AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0090-0036</gtr:issn><gtr:outcomeId>nez8jJeBqcu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F123FFA-BA25-4F73-B631-B9D7FAB378F5</gtr:id><gtr:title>Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d06d65b57027b1d3d31e886a00480e41"><gtr:id>d06d65b57027b1d3d31e886a00480e41</gtr:id><gtr:otherNames>Lactic Acidosis International Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>kkhJjzabZmj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD63BBE8-72A0-4ACE-B7F6-7064A13EF98A</gtr:id><gtr:title>Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eecf9ece12c8122b37c9ddd7ae1c75b0"><gtr:id>eecf9ece12c8122b37c9ddd7ae1c75b0</gtr:id><gtr:otherNames>Borges ?H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5464cea4204580.70322492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED10B90D-6BD6-4C33-8545-4CAE93D5C70F</gtr:id><gtr:title>Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b97465a4b060ca541e5d1714b00b1ca3"><gtr:id>b97465a4b060ca541e5d1714b00b1ca3</gtr:id><gtr:otherNames>Baker JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>kqKwyJY14M2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93CA55FB-A795-434E-9AA0-FC73A2C81C60</gtr:id><gtr:title>N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90d69989c8a7ee34f9bc879caac71c3f"><gtr:id>90d69989c8a7ee34f9bc879caac71c3f</gtr:id><gtr:otherNames>Duprez DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>D5fYc6VSRuT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCE79249-BB12-4CF3-A4F4-5B6B33246909</gtr:id><gtr:title>Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85763c2ccefcc71dc718b20f1f572a43"><gtr:id>85763c2ccefcc71dc718b20f1f572a43</gtr:id><gtr:otherNames>Cummins NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>5464cea4470627.70080420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08984862-93FC-443D-BBEE-3FD0007788F8</gtr:id><gtr:title>Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d3d35d367a42471775bc621386670a1"><gtr:id>1d3d35d367a42471775bc621386670a1</gtr:id><gtr:otherNames>English S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_15451_21_21736738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31C5658C-BF28-4D17-AA38-63D3645D4E06</gtr:id><gtr:title>Continuous antiretroviral therapy decreases bone mineral density.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5eb677ac90c24dd0cfe0c415652db9b"><gtr:id>a5eb677ac90c24dd0cfe0c415652db9b</gtr:id><gtr:otherNames>Grund B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>K1BKgCN2P7A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3F9CB2A-1895-43FA-AC50-3A15B4841F97</gtr:id><gtr:title>Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183477fd03e755ffd093359907ffb43e"><gtr:id>183477fd03e755ffd093359907ffb43e</gtr:id><gtr:otherNames>Phillips AN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pToq6KC4vzj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C58B318B-C7F8-430E-9E80-0681E8A706E6</gtr:id><gtr:title>Interleukin-2 therapy in patients with HIV infection.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bed0fd85210a60bc966a580081de4d30"><gtr:id>bed0fd85210a60bc966a580081de4d30</gtr:id><gtr:otherNames>INSIGHT-ESPRIT Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>aYY6MWhXYyz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8DC80B4-FE9D-4E18-81A9-32575AE4DDDB</gtr:id><gtr:title>Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545b58b6ede154.14086100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5259021-1EA3-4D3C-82E9-62D4C0A436C1</gtr:id><gtr:title>Short-course antiretroviral therapy in primary HIV infection.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/306b2be0b9e5d27387f4d49625940343"><gtr:id>306b2be0b9e5d27387f4d49625940343</gtr:id><gtr:otherNames>Weber J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_15451_21_23697518</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF935817-F950-4D0F-A483-B52519A91795</gtr:id><gtr:title>Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15451_21_22313951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88ACFDED-271F-4A29-9F57-C92420D1979B</gtr:id><gtr:title>Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts &amp;lt; 200 cells/microl.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/300bcd2c5353d921955a498aa2888782"><gtr:id>300bcd2c5353d921955a498aa2888782</gtr:id><gtr:otherNames>DART Trial Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>DbcjrpFXVsV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3D80254-7B6E-4E9A-A743-EABA95350767</gtr:id><gtr:title>Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc9fb93634c1fe15a1e4d500de41807f"><gtr:id>cc9fb93634c1fe15a1e4d500de41807f</gtr:id><gtr:otherNames>Bernardino JI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>56e053454129a5.52553036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25C02C5C-22B1-406C-A0FA-548D88011B98</gtr:id><gtr:title>HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3583e3b7afc8611b8cd7c4a38660e23"><gtr:id>c3583e3b7afc8611b8cd7c4a38660e23</gtr:id><gtr:otherNames>Harrison L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>56e0534270dd51.96721365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66D1D7D8-E786-4EF1-9D3B-459CE23275F5</gtr:id><gtr:title>TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/359027d0cec2737658589923e51bc651"><gtr:id>359027d0cec2737658589923e51bc651</gtr:id><gtr:otherNames>Angus B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>ax3cCZSNGo4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8274015-9E8F-4D56-BC24-7CA35E4D7497</gtr:id><gtr:title>Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6044d1bc57187297b6d30db6d3decedd"><gtr:id>6044d1bc57187297b6d30db6d3decedd</gtr:id><gtr:otherNames>Rodger AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>su3Tvc6dhVs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E40E985-D47D-46A0-85F4-4BD32003C36B</gtr:id><gtr:title>Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0273dd103e257f1782539313e806d79c"><gtr:id>0273dd103e257f1782539313e806d79c</gtr:id><gtr:otherNames>Cozzi-Lepri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>DCm22SYm1ZF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26FC7208-9DCE-4342-853A-1E37AAC69C52</gtr:id><gtr:title>Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bfadaa2ae6a1c4a244d8af47cf09bbba"><gtr:id>bfadaa2ae6a1c4a244d8af47cf09bbba</gtr:id><gtr:otherNames>Miller CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5464d0077cd686.44391708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB35088C-8185-4416-8246-665E0D02BCD8</gtr:id><gtr:title>The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a33fa6051a8ca7b043ffc187a316bff"><gtr:id>4a33fa6051a8ca7b043ffc187a316bff</gtr:id><gtr:otherNames>Ford D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>56e05344c698b1.40384058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CCD95F1-AA1E-4B47-98C3-6AB9421A3D89</gtr:id><gtr:title>Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study.</gtr:title><gtr:parentPublicationTitle>Journal of electrocardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1dc4a8166f3451f21dd1278fc669e5e5"><gtr:id>1dc4a8166f3451f21dd1278fc669e5e5</gtr:id><gtr:otherNames>Soliman EZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-0736</gtr:issn><gtr:outcomeId>jy2sMMZzKSj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A01AA45B-C885-46AB-8A6D-45046FB52E6B</gtr:id><gtr:title>Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study).</gtr:title><gtr:parentPublicationTitle>The American journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e77831b3f518f88d775fda5068f9be7"><gtr:id>5e77831b3f518f88d775fda5068f9be7</gtr:id><gtr:otherNames>Dawood FZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9149</gtr:issn><gtr:outcomeId>pm_15451_21_23062314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF14AB71-5B24-4455-BFE4-5706CBA0B47E</gtr:id><gtr:title>Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9654d2860d955eb2eb0308a6934be87f"><gtr:id>9654d2860d955eb2eb0308a6934be87f</gtr:id><gtr:otherNames>Lifson AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56dd98b6e32d20.74553529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A888B08-E20E-4CD1-AEB4-12AEF02B14D9</gtr:id><gtr:title>The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e75903e4560140d1d24a76d8561ab0fa"><gtr:id>e75903e4560140d1d24a76d8561ab0fa</gtr:id><gtr:otherNames>Davey RT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15451_21_23468921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7483BBA-AF34-4967-81AC-4D153AABB435</gtr:id><gtr:title>Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/791d70d1b9c052efe6e6ef98b35fa690"><gtr:id>791d70d1b9c052efe6e6ef98b35fa690</gtr:id><gtr:otherNames>INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56e053460888f5.11580662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCD77281-6D74-4AF0-9CDB-17B60FBCA74A</gtr:id><gtr:title>Antiretroviral treatment of primary HIV infection to reduce onward transmission.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07bf0be271190c882172ed692f8220f2"><gtr:id>07bf0be271190c882172ed692f8220f2</gtr:id><gtr:otherNames>Hamlyn E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>pm_15451_21_20543602</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122886352</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>